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A B S T R A C T
Background
Hepatic veno-occlusive disease (VOD) is a severe complication aJer haematopoietic stem cell transplantation (HSCT). DiKerent drugs with
diKerent mechanisms of action have been tried in HSCT recipients to prevent hepatic VOD. However, it is uncertain whether high-quality
evidence exists to support any prophylactic therapy.
Objectives
We aimed to determine the eKects of various prophylactic therapies on the incidence of hepatic VOD, overall survival, mortality, quality of
life (QOL), and the safety of these therapies in people undergoing HSCT.
Search methods
We searched the Cochrane Central Registe of Controlled Trials (CENTRAL), MEDLINE, EMBASE, conference proceedings of three
international haematology-oncology societies and two trial registries in January 2015, together with reference checking, citation searching
and contact with study authors to identify additional studies.
Selection criteria
We included randomised controlled trials (RCTs) comparing prophylactic therapies with placebo or no treatment, or comparing diKerent
therapies for hepatic VOD in people undergoing HSCT.
Data collection and analysis
We used standard methodological procedures expected by Cochrane.
Main results
We included 14 RCTs. Four trials (612 participants) compared ursodeoxycholic acid with or without additional treatment versus placebo or
no treatment or same additional treatment. Two trials (259 participants) compared heparin with no treatment. Two trials (106 participants)
compared low molecular weight heparin (LMWH) with placebo or no treatment. One trial (360 participants) compared defibrotide with no
treatment. One trial (34 participants) compared glutamine with placebo. Two trials (383 participants) compared fresh frozen plasma (FFP)
with or without additional treatment versus no treatment or same additional treatment. One trial (30 participants) compared antithrombin
III with heparin versus heparin. One trial compared heparin (47 participants) with LMWH (46 participants) and prostaglandin E1 (PGE1)
(47 participants). No trial investigated the eKects of danaparoid. The RCTs included participants of both genders with wide age range
and disease spectrum undergoing autologous or allogeneic HSCT. Funding was provided by government sources (two studies), research
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fund (one study), pharmaceutical companies that manufactured defibrotide and ursodeoxycholic acid (two studies), or unclear source
(nine studies). All RCTs had high risk of bias because of lack of blinding of participants and study personnel, or other risks of bias (mainly
diKerences in baseline characteristics of comparison groups).
Results showed that ursodeoxycholic acid may reduce the incidence of hepatic VOD (risk ratio (RR) 0.60, 95% confidence interval (CI) 0.40
to 0.88; number needed to treat for an additional beneficial outcome (NNTB) 15, 95% CI 7 to 50, low quality of evidence), but there was
no evidence of diKerence in overall survival (hazard ratio (HR) 0.83, 95% CI 0.59 to 1.18, low quality of evidence). It may reduce all-cause
mortality (RR 0.70, 95% CI 0.50 to 0.99; NNTB 17, 95% CI 8 to 431, low quality of evidence) and mortality due to hepatic VOD (RR 0.27, 95%
CI 0.09 to 0.87; NNTB 34, 95% CI 16 to 220, very low quality of evidence). There was no evidence of diKerence in the incidence of hepatic
VOD between treatment and control groups for heparin (RR 0.47, 95% CI 0.18 to 1.26, very low quality of evidence), LMWH (RR 0.27, 95% CI
0.06 to 1.18, very low quality of evidence), defibrotide (RR 0.62, 95% CI 0.38 to 1.02, low quality of evidence), glutamine (no hepatic VOD in
either group, very low quality of evidence), FFP (RR 0.66, 95% CI 0.20 to 2.17, very low quality of evidence), antithrombin III (RR 0.13, 95% CI
0.01 to 2.15, very low quality of evidence), between heparin and LMWH (RR 1.96, 95% CI 0.80 to 4.77, very low quality of evidence), between
heparin and PGE1 (RR 1.20, 95% CI 0.58 to 2.50, very low quality of evidence), and between LMWH and PGE1 (RR 0.61, 95% CI 0.24 to 1.55,
very low quality of evidence). There was no evidence of diKerence in survival between treatment and control groups for heparin (92.6% vs.
88.7%) and defibrotide (HR 1.04, 95% CI 0.54 to 2.02, low quality of evidence). There were no data on survival for trials of LMWH, glutamine,
FFP, antithrombin III, between heparin and LMWH, between heparin and PGE1, and between LMWH and PGE1. There were no data on
quality of life (QoL) for any trials. Eleven trials reported adverse events. There was no evidence of diKerence in the frequency of adverse
events between treatment and control groups except for one trial showing that defibrotide resulted in more adverse events compared with
no treatment (RR 18.79, 95% CI 1.10 to 320.45). These adverse events included coagulopathy, gastrointestinal disorders, haemorrhage and
microangiopathy. The quality of evidence was low or very low due to bias of study design, and inconsistent and imprecise results.
Authors' conclusions
There is low or very low quality evidence that ursodeoxycholic acid may reduce the incidence of hepatic VOD, all-cause mortality and
mortality due to VOD in HSCT recipients. However, the optimal regimen is not well-defined. There is insuKicient evidence to support the
use of heparin, LMWH, defibrotide, glutamine, FFP, antithrombin III, and PGE1. Further high-quality RCTs are needed.
P L A I N   L A N G U A G E   S U M M A R Y
Prevention of occlusion of small veins in the liver a5er blood-forming stem cell transplantation
Review Question
We reviewed evidence about the eKects of medications to prevent blockage of small veins in the liver (veno-occlusive disease or VOD) in
people who undergo blood-forming stem cell transplantation (HSCT).
Background
People undergoing HSCT can develop VOD, a severe complication which may lead to their death. Various medications with diKerent
mechanisms of action have been tried to prevent VOD. These prophylactic measures include heparin, low molecular weight heparin
(LMWH), danaparoid, ursodeoxycholic acid, prostaglandin E1 (PGE1), glutamine, antithrombin III, defibrotide and fresh frozen plasma
(FFP). Many transplant centres routinely administer these preventive measures, especially for people at high risk.
Study Characteristics
We included 14 randomised controlled trials (RCTs). Four trials (612 participants) compared ursodeoxycholic acid with or without
additional treatment versus placebo or no treatment or the same additional treatment. Two trials (259 participants) compared heparin
with no treatment. Two trials (106 participants) compared low molecular weight heparin with placebo or no treatment. One trial (360
participants) compared defibrotide with no treatment. One trial (34 participants) compared glutamine with placebo. Two trials (383
participants) compared fresh frozen plasma with or without additional treatment versus no treatment or the same additional treatment.
One trial (30 participants) compared antithrombin III with heparin versus heparin alone. One trial compared heparin (47 participants)
with LMWH (46 participants) and prostaglandin E1 (47 participants). No trial investigated the eKects of danaparoid. The RCTs included
participants of both genders with a wide age range and disease spectrum undergoing HSCT. The evidence is current as of January 2015.
Key Results
Ursodeoxycholic acid may reduce the occurrence of VOD, deaths from all causes and deaths due to VOD, but there was no evidence of a
diKerence in overall survival. There was no evidence of diKerence in occurrence of VOD between treatment and control groups for heparin,
LMWH, defibrotide, glutamine, FFP, antithrombin III, between heparin and LMWH, between heparin and PGE1, and between LMWH and
PGE1. There was no evidence of diKerence in survival between treatment and control groups for heparin and defibrotide. There were
no data on survival for trials of LMWH, glutamine, FFP, antithrombin III, between heparin and LMWH, between heparin and PGE1, and
between LMWH and PGE1. There were no data on quality of life for any trials. Eleven trials reported adverse eKects. There was no evidence
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of a diKerence in adverse events among treatment groups, except for one trial showing that defibrotide resulted in more adverse events
compared with no treatment.
Quality of the Evidence
The quality of evidence for all outcomes was low to very low, because of high risk of bias in study design, results inconsistent across studies
and imprecision of results.
Conclusion
There is low or very low quality evidence that ursodeoxycholic acid may reduce the incidence of hepatic VOD, overall mortality and
mortality due to VOD in people undergoing HSCT. However, the most eKective treatment is not well-defined. There is insuKicient evidence
to support the use of heparin, low molecular weight heparin, defibrotide, glutamine, FFP, antithrombin III, and prostaglandin E1. Further
high-quality research is needed.
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Summary of findings for the main comparison.   Summary of findings: Ursodeoxycholic acid versus placebo or no treatment
Ursodeoxycholic acid compared with placebo or no treatment for prophylaxis of hepatic veno-occlusive disease
Patient or population: People undergoing stem cell transplant with a variety of malignant and non-malignant diseases
Settings: Inpatients
Intervention: Ursodeoxycholic acid
Comparison: Placebo or no treatment
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
Placebo or no
treatment
Ursodeoxycholic acid
Relative effect
(95% CI)
No of Partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Incidence of hepatic veno-occlu-
sive disease
(follow-up: 24 weeks to 1 year)
189 per 10003 113 per 1000
(75 to 167)
RR 0.60 (0.40 to 0.88) 612
(4)
⊕⊕⊝⊝
low1
 
Overall survival
(follow-up: 1 year)
594 per 10003 663 per 1000
(520 to 760)
HR 0.83 (0.59 to 1.18) 474
(3)
⊕⊕⊝⊝
low1
 
All-cause mortality at 100 days
post-transplant
(follow-up: 100 days)
223 per 10003 156 per 1000
(111 to 221)
RR 0.70 (0.50 to 0.99) 612
(4)
⊕⊕⊝⊝
low1
 
Mortality attributable to hepatic
veno-occlusive disease
(follow-up: 24 weeks to 1 year)
38 per 10003 10 per 1000
(3 to 33)
RR 0.27 (0.09 to 0.87) 612
(4)
⊕⊝⊝⊝
very low2
 
Quality of life Not reported Not applicable Not applicable Not reported Not applica-
ble
 
Frequency of adverse events 27 per 10004 24 per 1000
(9 to 60)
RR 0.90 (0.37 to 2.22) 612
(4)
⊕⊝⊝⊝
very low2
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(follow-up: 24 weeks to 1 year)
*The assumed risk is the median control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the compari-
son group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; HR: Hazard ratio; RR: Risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1. Evidence from RCT downgraded by 2 levels because of high risk of bias in study design (serious) and heterogeneity among the studies (serious)
2. Evidence from RCT downgraded by 3 levels because of high risk of bias in study design (serious), heterogeneity among the studies (serious) and imprecision of results (serious)
3. The assumed risk is the median control group risk across studies
4. The assumed risk is the average of control group risk across studies as three out of four control group risks are zero
 
 
Summary of findings 2.   Summary of findings: Heparin versus no treatment
Heparin compared with no treatment for prophylaxis of hepatic veno-occlusive disease
Patient or population: People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia
Settings: Inpatients
Intervention: Heparin
Comparison: No treatment
Illustrative comparative risks* (95%
CI)
Assumed risk Corresponding risk
Outcomes
No treatment Heparin
Relative effect
(95% CI)
No of Partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Incidence of hepatic veno-occlusive dis-
ease
(follow-up: 100 days)
80 per 10004 38 per 1000
(14 to 101)
RR 0.47 (0.18 to
1.26)
259
(2)
⊕⊝⊝⊝
very low1
 
Overall survival
(follow-up: 100 days)
887 per 10004 926 per 1000 HR 0.65 161
(1)
⊕⊝⊝⊝
very low2
Data were not available
for calculation of confi-
dence intervals
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All-cause mortality at 100 days post-
transplant
(follow-up: 100 days)
113 per 10004 75 per 1000
(28 to 199)
RR 0.66 (0.25 to
1.76)
161
(1)
⊕⊕⊝⊝
low3
 
Mortality attributable to hepatic veno-
occlusive disease
(follow-up: 100 days)
88 per 10004 25 per 1000
(5 to 199)
RR 0.28 (0.06 to
1.32)
161
(1)
⊕⊕⊝⊝
low3
 
Quality of life Not reported Not applicable Not applicable Not reported Not applica-
ble
 
Frequency of adverse events
(follow-up: 100 days)
0 per 10004 37 per 1000 RR 6.91 (0.36 to
131.75)
161
(1)
⊕⊝⊝⊝
very low2
Control group risk (and
assumed risk) is zero.
Corresponding risk is
based on treatment
group risk.
*The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in
the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; HR: Hazard ratio; RR: Risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1. Evidence from RCT downgraded by 3 levels because of high risk of bias in study design (serious), heterogeneity among the studies (serious) and imprecision of results (serious)
2. Evidence from RCT downgraded by 3 levels because of high risk of bias in study design (serious) and gross imprecision of results (very serious)
3. Evidence from RCT downgraded by 2 levels because of high risk of bias in study design (serious) and imprecision of results (serious)
4. The assumed risk is the median control group risk across studies
 
 
Summary of findings 3.   Summary of findings: Low molecular weight heparin versus placebo or no treatment
Low molecular weight heparin compared with placebo or no treatment for prophylaxis of hepatic veno-occlusive disease
Patient or population: People undergoing stem cell transplant with malignant diseases
Settings: Inpatients
Intervention: Low molecular weight heparin
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Comparison: Placebo or no treatment
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
Placebo or no treat-
ment
Low molecular weight he-
parin
Relative effect
(95% CI)
No of Partici-
pants
(studies)
Quality of the evi-
dence
(GRADE)
Comments
Incidence of hepatic veno-
occlusive disease
(follow-up: unclear)
318 per 10002 86 per 1000
(19 to 376)
RR 0.27 (0.06 to 1.18) 45
(1)
⊕⊝⊝⊝
very low1
 
Overall survival Not reported Not applicable Not applicable Not reported Not applicable  
All-cause mortality at 100
days post-transplant
Not reported Not applicable Not applicable Not reported Not applicable  
Mortality attributable to he-
patic veno-occlusive disease
Not reported Not applicable Not applicable Not reported Not applicable  
Quality of life Not reported Not applicable Not applicable Not reported Not applicable  
Frequency of adverse
events
(follow-up: unclear)
242 per 10002 179 per 1000
(65 to 484)
RR 0.74 (0.27 to 2.00) 61
(1)
⊕⊝⊝⊝
very low1
 
*The basis for the assumed risk is the control group risk. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group
and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1. Evidence from RCT downgraded by 3 levels because of high risk of bias in study design (serious) and gross imprecision of results (very serious).
2. The assumed risk is the control group risk
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Summary of findings 4.   Summary of findings: Defibrotide versus no treatment
Defibrotide compared with no treatment for prophylaxis of hepatic veno-occlusive disease
Patient or population: Children undergoing stem cell transplant with malignant and non-malignant diseases and risk factors for hepatic veno-occlusive disease
Settings: Inpatients
Intervention: Defibrotide
Comparison: No treatment
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
No treatment Defibrotide
Relative effect
(95% CI)
No of Partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Incidence of hepatic veno-occlusive dis-
ease
(follow-up: 180 days)
196 per 10003 122 per 1000
(74 to 200)
RR 0.62 (0.38 to 1.02) 360
(1)
⊕⊕⊝⊝
low1
 
Overall survival
(follow-up: 180 days)
903 per 10003 899 per 1000
(804 to 948)
HR 1.04 (0.54 to 2.02) 356
(1)
⊕⊕⊝⊝
low1
 
All-cause mortality at 100 days post-trans-
plant
(follow-up: 100 days)
95 per 10003 100 per 1000
(53 to 188)
RR 1.05 (0.56 to 1.97) 360
(1)
⊕⊕⊝⊝
low1
 
Mortality attributable to hepatic veno-oc-
clusive disease
(follow-up: 180 days)
56 per 10003 22 per 1000
(7 to 70)
RR 0.40 (0.13 to 1.24) 360
(1)
⊕⊕⊝⊝
low1
 
Quality of life Not reported Not applicable Not applicable Not reported Not applica-
ble
 
Frequency of adverse events
(follow-up: 180 days)
0 per 10003 50 per 1000 RR 18.79 (1.10 to
320.45)
360
(1)
⊕⊝⊝⊝
very low2
Control group
risk (and as-
sumed risk)
is zero. Cor-
responding
risk is based
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on treatment
group risk.
*The basis for the assumed risk is the control group risk. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group
and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; HR: Hazard ratio; RR: Risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1. Evidence from RCT downgraded by 2 levels because of high risk of bias in study design (serious) and imprecision of results (serious)
2. Evidence from RCT downgraded by 3 levels because of high risk of bias in study design (serious) and gross imprecision of results (very serious)
3. The assumed risk is the control group risk
 
 
Summary of findings 5.   Summary of findings: Glutamine versus placebo
Glutamine compared with placebo for prophylaxis of hepatic veno-occlusive disease
Patient or population: People undergoing stem cell transplant with haematological malignancies
Settings: Inpatients
Intervention: Glutamine
Comparison: Placebo
Illustrative comparative risks*
(95% CI)
Assumed risk Corresponding
risk
Outcomes
Placebo Glutamine
Relative effect
(95% CI)
No of Partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Incidence of hepatic veno-occlu-
sive disease
(follow-up: till discharge from BMT
unit)
0 per 10002 0 per 1000 RR not es-
timable
34
(1)
⊕⊝⊝⊝
very low1
No participant developed hepatic veno-
occlusive disease in either the treatment
or control groups
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Overall survival Not reported Not applicable Not applicable Not reported Not applica-
ble
 
All-cause mortality at 100 days
post-transplant
(follow-up: 100 days)
63 per 10002 19 per 1000
(0 to 431)
RR 0.30 (0.01 to
6.84)
34
(1)
⊕⊝⊝⊝
very low1
 
Mortality attributable to hepatic
veno-occlusive disease
(follow-up: till discharge from BMT
unit)
0 per 10002 0 per 1000 RR not es-
timable
34
(1)
⊕⊝⊝⊝
very low1
No participant developed hepatic veno-
occlusive disease in either the treatment
or control groups
Quality of life Not reported Not applicable Not applicable Not reported Not applica-
ble
 
Frequency of adverse events
(follow-up: till discharge from BMT
unit)
0 per 10002 56 per 1000 RR 2.68 (0.12 to
61.58)
34
(1)
⊕⊝⊝⊝
very low1
Control group risk (and assumed risk)
is zero. Corresponding risk is based on
treatment group risk.
*The basis for the assumed risk is the control group risk. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group
and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk Ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1. Evidence from RCT downgraded by 3 levels because of high risk of bias in study design (serious) and gross imprecision of results (very serious)
2. The assumed risk is the control group risk
 
 
Summary of findings 6.   Summary of findings: Fresh frozen plasma versus no treatment
Fresh frozen plasma compared with no treatment for prophylaxis of hepatic veno-occlusive disease
Patient or population: People undergoing stem cell transplants with malignant and non-malignant diseases
Settings: Inpatients
Intervention: Fresh frozen plasma
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Comparison: no treatment
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
No treatment Fresh frozen plasma
Relative effect
(95% CI)
No of Partici-
pants
(studies)
Quality of the evi-
dence
(GRADE)
Comments
Incidence of hepatic veno-
occlusive disease
(follow-up: 28-100 days)
78 per 10002 51 per 1000
(15 to 170)
RR 0.66 (0.20 to 2.17) 383
(2)
⊕⊝⊝⊝
very low1
 
Overall survival Not reported Not applicable Not applicable Not reported Not applicable  
All-cause mortality at 100
days post-transplant
Not reported Not applicable Not applicable Not reported Not applicable  
Mortality attributable to he-
patic veno-occlusive disease
Not reported Not applicable Not applicable Not reported Not applicable  
Quality of life Not reported Not applicable Not applicable Not reported Not applicable  
Frequency of adverse
events
Not reported Not applicable Not applicable Not reported Not applicable  
*The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in
the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1. Evidence from RCT downgraded by 3 levels because of high risk of bias in study design (serious), heterogeneity among the studies (serious) and imprecision of results (serious)
2. The assumed risk is the control group risk
 
 
Summary of findings 7.   Summary of findings: Antithrombin III plus heparin versus heparin alone
Antithrombin III plus heparin compared with heparin alone for prophylaxis of hepatic veno-occlusive disease
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Patient or population: People undergoing stem cell transplant with malignant and non-malignant diseases
Settings: Inpatients
Intervention: Antithrombin III plus heparin
Comparison: Heparin alone
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
Heparin alone Antithrombin III plus he-
parin
Relative effect
(95% CI)
No of Partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Incidence of hepatic veno-occlusive
disease
(follow-up: unclear)
250 per 10002 33 per 1000
(2 to 538)
RR 0.13 (0.01 to
2.15)
30
(1)
⊕⊝⊝⊝
very low1
 
Overall survival Not reported Not applicable Not applicable Not reported Not applicable  
All-cause mortality at 100 days post-
transplant
Not reported Not applicable Not applicable Not reported Not applicable  
Mortality attributable to hepatic
veno-occlusive disease
(follow-up: unclear)
0 per 10002 0 per 1000 RR not estimable 30
(1)
⊕⊝⊝⊝
very low1
No participant
died of hepat-
ic veno-occlu-
sive disease in
either the treat-
ment or control
groups
Quality of life Not reported Not applicable Not applicable Not reported Not applicable  
Frequency of adverse events
(follow-up: unclear)
250 per 10002 73 per 1000
(10 to 568)
RR 0.29 (0.04 to
2.27)
30
(1)
⊕⊝⊝⊝
very low1
 
*The basis for the assumed risk is the control group risk. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group
and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
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Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1. Evidence from RCT downgraded by 3 levels because of high risk of bias in study design (serious) and gross imprecision of results (very serious)
2. The assumed risk is the control group risk
 
 
Summary of findings 8.   Summary of findings: Heparin versus low molecular weight heparin
Heparin compared with low molecular weight heparin for prophylaxis of hepatic veno-occlusive disease
Patient or population: Patients undergoing stem cell transplant with malignant and non-malignant diseases
Settings: Inpatients
Intervention: Heparin
Comparison:Low molecular weight heparin
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
Low molecular
weight heparin
Heparin
Relative effect
(95% CI)
No of Partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Incidence of hepatic veno-occlusive dis-
ease
(follow-up: unclear)
130 per 10002 255 per 1000
(104 to 621)
RR 1.96 (0.80 to
4.77)
93
(1)
⊕⊝⊝⊝
very low1
 
Overall survival Not reported Not applicable Not applicable Not reported Not applicable  
All-cause mortality at 100 days post-
transplant
Not reported Not applicable Not applicable Not reported Not applicable  
Mortality attributable to hepatic veno-
occlusive disease
(follow-up: unclear)
0 per 10002 21 per 1000 RR 2.94 (0.12 to
70.30)
93
(1)
⊕⊝⊝⊝
very low1
Control group
risk (and as-
sumed risk)
is zero. Corre-
sponding risk is
based on treat-
ment group
risk.
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Quality of life Not reported Not applicable Not applicable Not reported Not applicable  
Frequency of adverse events
(follow-up: unclear)
152 per 10002 128 per 1000
(45 to 352)
RR 0.84 (0.30 to
2.31)
93
(1)
⊕⊝⊝⊝
very low1
 
*The basis for the assumed risk is the control group risk. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group
and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1. Evidence from RCT downgraded by 3 levels because of high risk of bias in study design (serious) and gross imprecision of results (very serious)
2. The assumed risk is the control group risk
 
 
Summary of findings 9.   Summary of findings: Heparin versus prostaglandin E1
Heparin compared with prostaglandin E1 for prophylaxis of hepatic veno-occlusive disease
Patient or population: Patients undergoing stem cell transplant with malignant and non-malignant diseases
Settings: Inpatients
Intervention: Heparin
Comparison: Prostaglandin E1
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
Prostaglandin E1 Heparin
Relative effect
(95% CI)
No of Partici-
pants
(studies)
Quality of the evi-
dence
(GRADE)
Comments
Incidence of hepatic veno-oc-
clusive disease
(follow-up: unclear)
213 per 10002 255 per 1000
(123 to 533)
RR 1.20 (0.58 to 2.50) 94
(1)
⊕⊝⊝⊝
very low1
 
Overall survival Not reported Not applicable Not applicable Not reported Not applicable  
Cochrane
Library
Trusted evidence.
Inform
ed decisions.
Better health.
  
Cochrane Database of System
atic Review
s
Interventions for prophylaxis of hepatic veno-occlusive disease in people undergoing haem
atopoietic stem
 cell transplantation (Review
)
Copyright ©
 2015 The Cochrane Collaboration. Published by John W
iley & Sons, Ltd.
15
All-cause mortality at 100
days post-transplant
Not reported Not applicable Not applicable Not reported Not applicable  
Mortality attributable to he-
patic veno-occlusive disease
(follow-up: unclear)
43 per 10002 22 per 1000
(2 to 230)
RR 0.50 (0.05 to 5.33) 94
(1)
⊕⊝⊝⊝
very low1
 
Quality of life Not reported Not applicable Not applicable Not reported Not applicable  
Frequency of adverse events
(follow-up: unclear)
298 per 10002 128 per 1000
(53 to 304)
RR 0.43 (0.18 to 1.02) 94
(1)
⊕⊝⊝⊝
very low1
 
*The basis for the assumed risk is the control group risk. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group
and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1. Evidence from RCT downgraded by 3 levels because of high risk of bias in study design (serious) and gross imprecision of results (very serious)
2. The assumed risk is the control group risk
 
 
Summary of findings 10.   Summary of findings: Low molecular weight heparin versus prostaglandin E1
Low molecular weight heparin compared with prostaglandin E1 for prophylaxis of hepatic veno-occlusive disease
Patient or population: People undergoing stem cell transplant with malignant and non-malignant diseases
Settings: Inpatients
Intervention: Low molecular weight heparin
Comparison: Prostaglandin E1
Illustrative comparative risks* (95% CI)Outcomes
Assumed risk Corresponding risk
Relative effect
(95% CI)
No of Partici-
pants
(studies)
Quality of the evi-
dence
(GRADE)
Comments
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Prostaglandin E1 Low molecular weight he-
parin
Incidence of hepatic veno-
occlusive disease
(follow-up: unclear)
213 per 10002 130 per 1000
(51 to 331)
RR 0.61 (0.24 to 1.55) 93
(1)
⊕⊝⊝⊝
very low1
 
Overall survival Not reported Not applicable Not applicable Not reported Not applicable  
All-cause mortality at 100
days post-transplant
Not reported Not applicable Not applicable Not reported Not applicable  
Mortality attributable to he-
patic veno-occlusive disease
(follow-up: unclear)
43 per 10002 9 per 1000
(0 to 179)
RR 0.20 (0.01 to 4.14) 93
(1)
⊕⊝⊝⊝
very low1
 
Quality of life Not reported Not applicable Not applicable Not reported Not applicable  
Frequency of adverse
events
(follow-up: unclear)
298 per 10002 152 per 1000
(68 to 343)
RR 0.51 (0.23 to 1.15) 93
(1)
⊕⊝⊝⊝
very low1
 
*The basis for the assumed risk is the control group risk. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group
and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1. Evidence from RCT downgraded by 3 levels because of high risk of bias in study design (serious) and gross imprecision of results (very serious)
2. The assumed risk is the control group risk
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B A C K G R O U N D
Description of the condition
Haematopoietic stem cell transplantation (HSCT) is an important
treatment for many diKerent malignant and non-malignant
diseases. However, it is associated with various complications
which may result in death. Hepatic veno-occlusive disease (VOD),
also known as hepatic sinusoidal obstruction syndrome, is one
of the major complications of HSCT and is the leading cause of
transplant-related mortality. Up to 77% of transplant recipients
develop VOD aJer HSCT when prophylaxis is not given (Coppell
2010), with mortality of around 84% in severe cases despite
treatment (Coppell 2010). It can occur following both autologous
and allogeneic HSCT, regardless of the stem cell source, type of
conditioning, or underlying disease.
Diagnosis of hepatic VOD is based on a constellation of symptoms
and signs and serum bilirubin level. The most commonly used
diagnostic criteria for hepatic VOD include the Seattle criteria
(McDonald 1984), the modified Seattle criteria (McDonald 1993),
and the Baltimore criteria (Jones 1987). By the Seattle criteria,
hepatic VOD is diagnosed when two or more of the three criteria
(jaundice, hepatomegaly with right upper quadrant abdominal
pain, ascites or unexplained weight gain or both) are fulfilled. The
modified Seattle criteria require occurrence of at least two of the
following three events within 20 days post-HSCT: total bilirubin ≥ 2
mg/dL, hepatomegaly or right upper quadrant abdominal pain of
hepatic origin, or unexplained weight gain > 2% of baseline because
of fluid accumulation. The Baltimore criteria require an elevated
total bilirubin level (≥ 2 mg/dL) before day 21 post-HSCT and two
of the following three criteria: tender hepatomegaly, weight gain >
5% from baseline, or ascites. The severity of hepatic VOD is usually
categorised into three stages: mild, moderate, or severe, depending
on adverse eKects from hepatic VOD, treatment required, duration
of disease, and mortality (McDonald 1993).
The pathogenesis of hepatic VOD is incompletely understood.
The clinical manifestations of hepatic VOD are thought to be
caused by sinusoidal obstruction with or without occlusion of
intrahepatic central venules, resulting from dysfunction of hepatic
sinusoidal endothelial cells (SEC) (DeLeve 2002; Helmy 2006).
The cause of SEC dysfunction is multifactorial. Many diKerent
risk factors for hepatic VOD have been described. Conditioning
with busulfan with or without cyclophosphamide (Barker 2003;
Cesaro 2005; Cheuk 2007; Lee 2010; McDonald 1993; Song 2006)
or conditioning with total body irradiation (Hasegawa 1998; Lee
2010) are reported to be significant risk factors for hepatic VOD.
Busulfan has high inter-patient variability in pharmacokinetics
and increased exposure correlates with increased risk of hepatic
VOD (Krivoy 2008). Metabolites of busulfan or irradiation may
deplete the cellular pool of glutathione, which is an essential
antioxidant that protects hepatocytes and SEC from free radical
damage (Helmy 2006; McDonald 1993). Irradiation also increases
tumour necrosis factor alpha, which causes increased capillary
permeability and contributes to SEC and hepatocyte dysfunction
(Bearman 1995; Hallahan 1989). People of extreme age may
have a higher risk of developing hepatic VOD. The reasons are
uncertain. In children, the smaller calibre of hepatic venules
and relatively high busulfan concentration may predispose them
to develop hepatic VOD (Cesaro 2005; Cheuk 2007; Horn 2002).
In the elderly, pre-existing hepatic dysfunction and poorer
tolerance to hepatotoxic medications may increase their risk of
developing hepatic VOD (McDonald 1984; Toh 1999). Transplant
for thalassaemia major (Cheuk 2007) may also carry a higher risk
for hepatic VOD development. In people with thalassaemia, the
pre-existing iron overload and liver dysfunction may predispose
them to develop hepatic VOD when additional insults occur,
such as a busulfan-containing conditioning regimen (Cheuk
2007). Various malignancies, such as acute leukaemia (Ozkaynak
1991), neuroblastoma (Cesaro 2005; Horn 2002), or advanced
malignancies (Hasegawa 1998; Reiss 2002) may also carry a higher
risk of hepatic VOD compared with most non-malignant conditions
(Song 2006), as the cytotoxic chemotherapy may have caused
hepatocyte injury directly or indirectly through release of various
cytokines (Bearman 1995; Helmy 2006). Allogeneic HSCT using
an unrelated donor (Barker 2003; McDonald 1993; Reiss 2002;
Simon 2001) or human leukocyte antigen (HLA)-mismatched donor
(Hasegawa 1998; McDonald 1993) also increases the risk of hepatic
VOD, because the alloimmune T cells may release cytokines that
contribute to liver toxicity, particularly when acute graJ-versus-
host disease (GVHD) occurs (Antin 1992; Hasegawa 1998).
Since hepatic VOD can cause significant morbidity and mortality,
with some risk factors not modifiable and treatment of established
or severe hepatic VOD largely unsuccessful, many transplant
centres now administer routine prophylactic therapy to prevent the
occurrence of hepatic VOD in transplant recipients, especially in
high-risk patients. However, the medications and regimens used
are highly variable and no widely accepted recommendation or
guideline exists.
Description of the intervention
Prophylactic medications that have been used for hepatic VOD
in transplant recipients include heparin (Batsis 2006; Feldman
1996; Marsa-Vila 1991; Rosenthal 1996; Song 2006), low molecular
weight heparin (Forrest 2003; Or 1996; Styler 1996), danaparoid
(Sakaguchi 2010), ursodeoxycholic acid (Essell 1992; Thornley
2004), prostaglandin E1 (Gluckman 1990; Song 2006), glutamine
(Brown 1998), and defibrotide (Capelli 2009; Chalandon 2004;
Corbacioglu 2006; Dignan 2007; Qureshi 2008; Versluys 2004).
Some of these have also been tried in combinations (Simon
2001). Prophylaxis is generally given continuously from the
commencement of conditioning or the time of stem cell infusion
until neutrophil engraJment, or three to four weeks aJer HSCT,
during which hepatic VOD is most likely to develop. Some centres
administer hepatic VOD prophylaxis to all people undergoing HSCT,
while others will only give prophylaxis for those at high risk, with
variable criteria for 'high risk'.
How the intervention might work
Heparin is an anticoagulant which enhances the action of
the natural anticoagulant antithrombin in inhibiting multiple
coagulation factors including thrombin, factors VIIa, IXa, Xa, XIa,
and XIIa. Prophylactic heparin administration is intended to
prevent clot formation in hepatic venules, which is part of the
pathological changes in hepatic VOD. Heparin prophylaxis was
found to be associated with a low incidence of hepatic VOD in
some studies (10% to 20%) (Rosenthal 1996; Song 2006). Survival
at 100 days post-transplant was as high as 95% (Song 2006).
Mild haemorrhage occurred in 56% of participants in one study
(Rosenthal 1996). Combining heparin with fresh frozen plasma
might further reduce the incidence of hepatic VOD to 5.9% (Batsis
2006).
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Low molecular weight heparin, such as enoxaparin, is a derivative
of heparin with a similar mechanism of action. It has the advantage
of more predictable and stable anticoagulant eKects and thus
reduces the need for monitoring. It is injected subcutaneously
and does not require continuous intravenous infusion. It is also
less likely to cause significant adverse events, such as heparin-
induced thrombocytopenia or osteoporosis. Its use was found to be
associated with a low incidence of hepatic VOD (4% to 23%) (Forrest
2003; Simon 2001; Styler 1996). Overall survival at 100 days was 85%
in one study (Forrest 2003). Minor haemorrhage occurred in 60% of
participants and significant haemorrhage occurred in 1% to 8% of
participants (Forrest 2003; Simon 2001).
Danaparoid is a mixture of low molecular weight heparin,
chondroitin sulfate, and dermatan sulfate present in animal gut
mucosa. It renders factor Xa and thrombin inactive without
aKecting platelet function. It therefore promotes anticoagulation
with a lower bleeding tendency than heparin or low molecular
weight heparin. It also inhibits inflammatory cytokines (Iba 2008)
and may reduce the incidence of hepatic VOD (Sakaguchi 2010).
Only 2% of people developed hepatic VOD and 2% had significant
haemorrhage (Sakaguchi 2010).
Ursodeoxycholic acid is a hydrophilic bile acid which alters the
milieu of bile acids by making them less hydrophobic overall. Since
retention of hydrophobic bile acids was thought to contribute to
hepatocellular injury in cholestatic liver disease, ursodeoxycholic
acid might reduce hepatotoxicity induced by hepatotoxic
medications used during HSCT. Moreover, ursodeoxycholic acid
may attenuate the pro-inflammatory cytokine environment
through decreased expression of tumour necrosis factor alpha,
interleukin 1, interleukin 2, and interferon gamma, thereby
minimising endothelial injury (Yoshikawa 1992). Ursodeoxycholic
acid was found to prevent hepatic VOD in some clinical studies
(Essell 1992; Thornley 2004). The incidence of hepatic VOD ranged
from 3% to 9% (Essell 1992; Thornley 2004). The overall survival
at four years was 70% (Thornley 2004). No adverse event was
reported.
Prostaglandin E1 is a vasodilator with inhibitory eKects on
platelet aggregation, which may therefore prevent clotting of the
hepatic venules and prevent hepatic VOD from developing or
progressing. Some studies showed that continuous prostaglandin
E1 administration was associated with reduced incidence of
hepatic VOD (Gluckman 1990; Lee 2010; Song 2006). Hepatic VOD
occurred in 12% to 35% of participants (Gluckman 1990; Song 2006)
and survival at 100 days post-transplant was 92% to 95% in one
study (Song 2006). No adverse eKect was reported.
Glutamine is the precursor for production of glutathione, which is
an essential antioxidant that protects hepatocytes and endothelial
cells from oxidative damage by free radicals and activated
chemotherapeutic metabolites (Teicher 1988). Glutamine becomes
the rate-limiting factor in the production of glutathione by the
liver during periods of catabolic stress. Glutathione depletion is
hypothesised to be an essential component in the pathogenesis
of hepatic VOD (Helmy 2006). By increasing production of
glutathione, glutamine may prevent the development of hepatic
VOD. Glutamine supplementation has led to preservation of protein
C and albumin levels early in the post-transplant period, which may
be associated with a reduced risk of hepatic VOD (Brown 1998).
Among 18 participants who received glutamine, none developed
hepatic VOD and all survived the initial post-transplant period
(Brown 1998). No adverse event was reported.
Defibrotide is a mixture of single-stranded oligonucleotide. It
binds to endothelial cells via adenosine receptors A1 and A2
(Bianchi 1993), which may protect endothelial cells in response
to injury. It increases endogenous production of prostaglandin
I2, prostaglandin E2 (Coccheri 1988), and thrombomodulin
(Zhou 1994), which inhibit platelet activities and coagulation.
It also decreases thrombin generation and thrombin-induced
platelet aggregation (Bracht 1994), and promotes fibrinolysis via
upregulation of tissue factor pathway inhibitor (Cella 2001) and
tissue plasminogen activator (Falanga 2003; Pasini 1996), reduction
of plasminogen activator inhibitor 1 (Falanga 2003; Pasini 1996),
and enhancement of plasmin activity (Echart 2009). Some clinical
studies found defibrotide to be eKective in preventing hepatic VOD,
which occurred in 0% to 11% of those given prophylaxis (Capelli
2009; Chalandon 2004; Corbacioglu 2006; Dignan 2007; Qureshi
2008; Versluys 2004). Overall survival at 100 days post-transplant
ranged from 89% to 100% (Chalandon 2004; Corbacioglu 2006;
Dignan 2007; Versluys 2004). No adverse event was reported.
Why it is important to do this review
Hepatic VOD is a severe complication of haematopoietic stem cell
transplantation with high mortality and therefore prevention is
an obvious priority. However, it remains uncertain whether the
aforementioned preventive medications are based on high-quality
evidence. It is therefore important to perform a systematic review
to ascertain which medications are eKective for prevention of
hepatic VOD and to assess the quality of evidence. This is essential
for the development of clinical guidelines in the future.
O B J E C T I V E S
We aimed to determine the eKects of various prophylactic therapies
on incidence of hepatic VOD, overall survival, mortality, quality of
life (QOL), and the safety of these therapies in people undergoing
HSCT.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We only include randomised controlled trials (RCTs) in the review.
Types of participants
We include people of all ages who were undergoing haematopoietic
stem cell transplantation (HSCT) for any indication.
Types of interventions
We include trials evaluating prophylactic medications for hepatic
veno-occlusive disease (VOD) in the review. The interventions
might include heparin, low molecular weight heparin, danaparoid,
ursodeoxycholic acid, prostaglandin, glutamine, defibrotide, or
others. The control interventions could be placebo or no
intervention. We also include trials comparing alternative regimens
of the same medication or comparing diKerent medications.
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Types of outcome measures
We have not used the outcomes listed below as criteria for inclusion
of studies.
Primary outcomes
1. Incidence of hepatic VOD (proportion of participants who
developed hepatic VOD during the study period)
2. Overall survival (reported as time-to-event data)
Secondary outcomes• All-cause mortality (proportion of participants who died)
(Mortality reported at diKerent time points are analysed
separately)• Mortality attributable to hepatic VOD (proportion of participants
who died due to hepatic VOD during the study period)• Quality of life (measured by any validated scales at any time
point aJer treatment)• Frequency of adverse events (proportion of participants who
experienced adverse eKects) (All adverse events, severe adverse
events and specific adverse events are analysed separately)
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Trials
(CENTRAL) (28 January 2015), MEDLINE (OVID, 1966 to 28 January
2015) and EMBASE (OVID, 1980 to 28 January 2015) (Lefebvre
2011). The search strategies for the diKerent electronic databases
(using a combination of controlled vocabulary and text word terms)
are shown in the appendices: CENTRAL (Appendix 1), MEDLINE
(Appendix 2), and EMBASE (Appendix 3).
Searching other resources
We also searched conference proceedings of the following annual
meetings, if not already included in CENTRAL, from 2000 to January
2015:
• American Society of Hematology (ASH);• American Society for Clinical Oncology (ASCO);• European Society for Medical Oncology (ESMO).
We also searched:
• the World Health Organization International Clinical Trials
Registry Platform (ICTRP) which registers clinical trials from
many diKerent countries (apps.who.int/trialsearch) (accessed
on 28 January 2015, using search terms 'veno-occlusive disease'
or 'sinusoidal obstruction syndrome');• the meta-register of controlled trials (www.controlled-
trials.com/mrct/) (accessed on 28 January 2015, using search
terms 'veno-occlusive disease' or 'sinusoidal obstruction
syndrome').
We include articles published only in abstract form if the review
authors could be contacted to provide essential details for
appraisal and analysis. We searched reference lists of relevant
articles. Wecontacted authors of included studies to identify
possible unpublished studies. There was no language restriction
in the search and inclusion of studies. We considered multiple
publications reporting the same group of participants or its subsets
as a single study.
Data collection and analysis
Selection of studies
Two review authors (DKLC and AKSC) independently reviewed titles
and abstracts of references retrieved from the searches and select
all potentially relevant studies. The same review authors obtained
copies of these articles and reviewed them independently against
our pre-defined inclusion criteria (Higgins 2011a). Review authors
were not blinded to the names of the trial authors, institutions,
or journal of publication. We resolved all disagreements about
selection of studies by consensus. We report the flow of studies
as per the PRISMA statement in a flow chart, which contains data
on the number of records identified through database searching,
number of additional records identified through other sources,
number of records aJer duplicates removed, number of records
screened, number of records excluded, number of full-text articles
examined for eligibility, number of full-text articles excluded with
reasons, and numbers of studies included in qualitative and
quantitative syntheses.
Data extraction and management
Two review authors (DKLC and AKSC) independently extracted
data from included trials and entered them into a data collection
form (Higgins 2011a), resolving all disagreements by consensus.
We contacted the authors of included studies to provide essential
information that was missing from study reports. We extracted the
following data when available:
1. Study methods
a. Randomisation method (including list generation)
b. Method of allocation concealment
c. Blinding method
d. Stratification factor
2. Participants
a. Inclusion/exclusion criteria
b. Number (total/per group)
c. Age and gender distribution
d. Underlying diseases requiring HSCT
e. Previous treatments (chemotherapy, radiotherapy, HSCT)
f. Pre-existing liver dysfunction
g. Previous history of hepatic VOD
h. Performance status before transplant
i. Type of transplant (autologous, allogeneic)
j. Donor (family donor, unrelated donor)
k. Human leukocyte antigen (HLA) disparity
l. Stem cell source (bone marrow, peripheral blood stem cell,
cord blood)
m. Stem cell manipulation (T cell depletion, CD34+ cell
selection)
n. Conditioning regimen
o. GraJ-versus-host disease (GVHD) prophylaxis
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3. Intervention and control
a. Type of prophylactic intervention
b. Type of control
c. Details of prophylactic regimen and control
d. Details of co-interventions
4. Follow-up data
a. Duration of follow-up
b. Loss to follow-up with reasons
5. Outcome data as described above
6. Analysis data
a. Methods of analysis (intention-to-treat or per-protocol
analysis)
We entered the data into Review Manager 5 (RevMan) (RevMan
2014).
For overall survival data, we estimated the diKerence between
observed and expected event rate (O-E) and its variance from
reported event frequencies, as described by Tierney 2007.
Assessment of risk of bias in included studies
Two review authors (DKLC and AKSC) independently assessed
the quality of each eligible trial, resolving all disagreements by
consensus.
We included the following items to assess the methodological
quality of RCTs in accordance with the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011b):
1. Was the allocation sequence adequately generated?
2. Was allocation adequately concealed?
3. Blinding: was knowledge of the allocated interventions
adequately prevented during the study?
4. Were incomplete outcome data adequately addressed?
5. Were reports of the study free of suggestion of selective outcome
reporting?
6. Was the study apparently free of other problems that could put
it at a high risk of bias?
We planned to conduct sensitivity analyses to assess the impact of
risk of bias, by including and excluding studies at high risk of bias.
Measures of treatment e?ect
We used risk ratio (RR) estimates with 95% confidence intervals
(CIs) for binary outcomes. We used hazard ratio (HR) estimates
with 95% CI for time-to-event outcomes. We calculated the number
needed to treat for an additional beneficial outcome (NNTB)
estimates with 95% CI. We used mean diKerence (MD) estimates
with 95% CI for continuous outcome (Deeks 2011). All analyses
included all participants in the treatment groups to which they
were allocated (intention-to-treat analyses) if data were available.
Dealing with missing data
We contacted the authors of included studies to supply missing
data. We assessed missing data and dropouts for each included
study and assessed and discussed the extent to which the results
or conclusions of the review could be altered by the missing data
(Higgins 2011c). If fewer than 70% of participants allocated to the
treatments were reported on at the end of the trial for a particular
outcome, we considered those data to be prone to bias. We did
not impute missing data, except that for mortality and incidence
of hepatic VOD data we assumed that participants had not died or
developed VOD if their data were missing. Meta-analysis of time-
to-event data usually requires availability of individual patient data
from the original investigators (Higgins 2011a). Otherwise, we used
statistical methods according to Tierney 2007.
Assessment of heterogeneity
We assessed clinical heterogeneity by comparing the
distribution of important participant factors between trials
(age, underlying diseases, transplant characteristics) and trial
factors (randomisation concealment, blinding, losses to follow-up,
intervention regimens). We assessed statistical heterogeneity by
examining the I2 statistic (Deeks 2011), a quantity which describes
approximately the proportion of variation in point estimates due
to heterogeneity rather than to sampling error. We followed the
guide on interpretation of the I2 statistic suggested by the Cochrane
Handbook for Systematic Reviews of Interventions as follows:
• 0% to 40%: may not be important;• 30% to 60%: may represent moderate heterogeneity;• 50% to 90%: may represent substantial heterogeneity;• 75% to 100%: considerable heterogeneity.
In addition, we employed a Chi2 test of homogeneity to determine
the strength of evidence that heterogeneity was genuine. If
significant heterogeneity (P < 0.1) was present, we explored trials to
investigate possible explanations.
Assessment of reporting biases
We had planned to draw funnel plots (estimated diKerences
in treatment eKects against their standard errors) if we found
suKicient studies (at least 10) for a given outcome. Asymmetry
could be due to publication bias, but could also be due to a
relationship between trial size and eKect size. In the event that we
found a relationship, we would have examined clinical diversity
of the studies (Sterne 2011). However, there were fewer than ten
studies reporting the same outcome and we therefore did not draw
a funnel plot.
Data synthesis
Where the interventions were the same or similar enough, we
synthesised results in a meta-analysis if there was no important
clinical heterogeneity. We used the Review Manager 5 soJware
(RevMan 2014) to perform meta-analyses using a fixed-eKect model
(the generic inverse variance method for continuous data outcomes
and the Mantel-Haenszel method for dichotomous data outcomes)
(Deeks 2011). For multi-arm studies, we conducted analyses of
pair-wise comparisons. For meta-analyses, we did not combine
the results from participants of the same study into the same
meta-analysis more than once to avoid double counting. There
was also no arbitrary omission of relevant groups. We produced
'Summary of findings' tables according to the recommendations
in the Cochrane Handbook (Deeks 2011). These tables summarise
the results for the six pre-defined outcomes (incidence of hepatic
VOD, overall survival, all-cause mortality, mortality due to hepatic
VOD, quality of life, and frequency of adverse events) and provide
grading of the quality of evidence according to the GRADE system
(GRADEpro 2008; Schünemann 2011).
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Subgroup analysis and investigation of heterogeneity
If data permitted, we conducted subgroup analyses (Deeks 2011)
for:
1. DiKerent age groups (younger than 12 years, 12 to 18 years, 18 to
60 years, older than 60 years);
2. DiKerent types of underlying diseases (diKerent disease groups);
3. DiKerent types of transplant (autologous, family donor,
unrelated donor);
4. DiKerent HLA parity (HLA-matched, HLA-mismatched);
5. DiKerent transplant conditioning (radiation-based,
non-radiation-based, busulfan-containing, non-busulfan-
containing).
We defined these subgroups a priori. Participants in these
important subgroups might have diKerent susceptibility to hepatic
VOD and hence might have diKerent response to prophylactic
therapy.
We assessed subgroup diKerences by examining the I2 statistic and
performing a Chi2 test for heterogeneity across subgroup results.
Sensitivity analysis
We had planned to conduct sensitivity analyses to assess the
impact of study quality (Deeks 2011). These would include:
1. All studies;
2. Only those without high risk of bias in any aspect.
However, since all the included studies had a high risk of bias, we
did not perform a sensitivity analysis.
For outcomes with substantial heterogeneity, we would also have
performed random-eKects meta-analysis as a sensitivity analysis.
R E S U L T S
Description of studies
Results of the search
The electronic searches retrieved a total of 726 records (89
records from CENTRAL, 500 records from MEDLINE, and 137
records from EMBASE). Searching of Internet sources and
conference proceedings retrieved an additional 55 records. AJer
duplicates were removed, 622 records remained and were
screened. We obtained 25 full-text records. We excluded one study
(Characteristics of excluded studies). Two were ongoing studies
(Characteristics of ongoing studies). The remaining 22 records
describing 14 studies were included (Characteristics of included
studies). The flow of the studies is described in Figure 1.
 
Interventions for prophylaxis of hepatic veno-occlusive disease in people undergoing haematopoietic stem cell transplantation (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
21
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Figure 1.   Study flow diagram.
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Figure 1.   (Continued)
 
Included studies
Among the 14 included studies, 10 were published as full papers
(Attal 1992; Brown 1998; Corbacioglu 2012; Essell 1998; Marsa-Vila
1991; Matsumoto 2007; Ohashi 2000; Or 1996; Park 2002; Ruutu
2002) and four were published as abstracts only (Demuynck 1995;
Jung 2005; Lee 1996; Yannaki 2012). We contacted the authors
of all studies for missing information but none provided us with
useful results. The characteristics are described in the table of
Characteristics of included studies and are summarised below.
Two studies each were done in France (Attal 1992; Marsa-Vila
1991), Japan (Matsumoto 2007; Ohashi 2000), and Korea (Jung
2005; Park 2002). One study was done in 28 centres in Europe
(Corbacioglu 2012). One study was done in Finland and Sweden
(Ruutu 2002). One study each was done in USA (Essell 1998), UK
(Brown 1998), Belgium (Demuynck 1995), Greece (Yannaki 2012),
Israel (Or 1996), and Singapore (Lee 1996). Two studies were funded
by government sources (Marsa-Vila 1991; Matsumoto 2007), one
study was supported by a research fund (Or 1996), and two studies
were funded by pharmaceutical companies which manufactured
defibrotide (Corbacioglu 2012) and ursodeoxycholic acid (Essell
1998) respectively. The funding sources of the other studies were
unclear.
Design
All included studies were parallel-group randomised controlled
trials. Thirteen studies had two comparison groups (Attal 1992;
Brown 1998; Corbacioglu 2012; Essell 1998; Jung 2005; Lee 1996;
Marsa-Vila 1991; Matsumoto 2007; Ohashi 2000; Or 1996; Park 2002;
Ruutu 2002; Yannaki 2012) and one study had three comparison
groups (Demuynck 1995).
Sample sizes
The sample size of each included study ranged from 30 to 360
participants. Sample size calculation a priori was performed in six
studies (Attal 1992; Corbacioglu 2012; Essell 1998; Ohashi 2000;
Park 2002; Ruutu 2002)
Setting
All studies were carried out in the inpatient setting for people
undergoing HSCT.
Participants
The 14 included studies recruited a total of 1922 participants. All
studies included both men and women in similar proportions.
Six studies recruited both adults and children aged from one
to 64 years (Attal 1992; Brown 1998; Matsumoto 2007; Or 1996;
Ruutu 2002; Yannaki 2012), while four studies recruited adults only
(aged 18 to 56 years) (Essell 1998; Ohashi 2000; Marsa-Vila 1991;
Park 2002) and one study recruited children only (aged 0 to18
years) (Corbacioglu 2012). In three studies, the age distribution of
participants was not clear (Demuynck 1995; Jung 2005; Lee 1996).
Nine studies recruited participants with a variety of malignant
and non-malignant diseases (Attal 1992; Brown 1998; Corbacioglu
2012; Essell 1998; Jung 2005; Matsumoto 2007; Ohashi 2000; Park
2002; Ruutu 2002), while one study recruited only participants with
haematological malignancies (Lee 1996) and two studies recruited
only participants with haematological malignancies or solid
tumours (Marsa-Vila 1991; Or 1996). The participants' underlying
diseases were not described in two studies (Demuynck 1995;
Yannaki 2012). Only two studies (Essell 1998; Corbacioglu 2012)
described treatments that participants received prior to HSCT. Only
one study described the performance status prior to HSCT (Essell
1998). Eleven studies recruited both allogeneic and autologous
transplant recipients (Attal 1992; Brown 1998; Corbacioglu 2012;
Demuynck 1995; Jung 2005; Lee 1996; Ohashi 2000; Or 1996; Park
2002; Ruutu 2002; Yannaki 2012), while two studies recruited only
allogeneic transplant recipients (Essell 1998; Matsumoto 2007)
and one study recruited only autologous transplant recipients
(Marsa-Vila 1991). Stem cell source was bone marrow exclusively
in four studies (Attal 1992; Essell 1998; Lee 1996; Marsa-Vila 1991).
Either bone marrow or peripheral blood stem cell was used in
two studies (Brown 1998; Ruutu 2002); and cord blood was also
used in some participants in three studies (Corbacioglu 2012; Jung
2005; Matsumoto 2007). The stem cell source was not described
in five studies (Demuynck 1995; Ohashi 2000; Or 1996; Park 2002;
Yannaki 2012). A variety of conditioning regimen was used in nine
studies (Attal 1992; Brown 1998; Corbacioglu 2012; Matsumoto
2007; Ohashi 2000; Or 1996; Park 2002; Ruutu 2002; Yannaki 2012).
Only busulfan and cyclophosphamide were used in one study
(Essell 1998). In four studies (Demuynck 1995; Jung 2005; Lee
1996; Marsa-Vila 1991), authors did not describe the conditioning
regimen used. DiKerent GVHD prophylaxis was employed in four
studies (Corbacioglu 2012; Matsumoto 2007; Ohashi 2000; Ruutu
2002). In two studies (Attal 1992; Essell 1998), all allogeneic
transplant recipients received cyclosporin and methotrexate for
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GVHD prophylaxis. In seven studies (Brown 1998; Demuynck 1995;
Jung 2005; Lee 1996; Or 1996; Park 2002; Yannaki 2012), GVHD
prophylaxis was not described. In one study (Marsa-Vila 1991),
only autologous HSCT was performed and GVHD prophylaxis was
not applicable. Pre-existing liver dysfunction occurred in some
participants in four studies (Attal 1992; Corbacioglu 2012; Essell
1998; Or 1996). This was not described in the remaining ten studies.
History of hepatic VOD in participants was described in only one
study (Attal 1992).
Interventions
Four studies investigated the eKicacy of ursodeoxycholic acid,
with two studies comparing ursodeoxycholic acid with placebo
(Essell 1998; Ruutu 2002), one study comparing ursodeoxycholic
acid with no treatment (Ohashi 2000), and one study comparing
ursodeoxycholic acid plus heparin with heparin alone (Park 2002).
The dosing regimen of ursodeoxycholic acid was variable among
diKerent trials. One included trial used ursodeoxycholic acid at
300 mg twice daily from 12 to 24 hours before conditioning till
discharge or day 30 post-transplant (Park 2002). One trial used
600 mg per day from 21 days before stem cell infusion till day
80 post-transplant (Ohashi 2000). One trial used 6 mg/kg twice
daily from the day of conditioning till day 90 post-transplant
(Ruutu 2002). One trial used diKerent doses depending on body
weight categories from before the start of conditioning till day
80 post-transplant (Essell 1998). Two studies compared heparin
with no treatment (Attal 1992; Marsa-Vila 1991). The first study
(Attal 1992) used heparin at 100 units/kg/day from the start of
conditioning till 30 days post-transplant or discharge. The second
study (Marsa-Vila 1991) used heparin at 1 mg/kg/day from day
0 to haematological reconstitution and discharge. Two studies
investigated the eKicacy of low molecular weight heparin, with
one study comparing enoxaparin (40 mg daily from one day before
stem cell infusion till discharge or day 40 post-transplant) with
placebo (Or 1996), and one study comparing nadroparin with no
treatment (Lee 1996). One study compared defibrotide (6.25 mg/
kg/dose every 6 hours from the day of conditioning till day 30
post-transplant) with no treatment (Corbacioglu 2012). One study
compared glutamine (50 g daily from the start of conditioning till
discharge from the transplant unit) with placebo (Brown 1998).
One study compared fresh frozen plasma (FFP) (dosage according
to body weight, twice weekly from conditioning till day 28 post-
transplant) with no treatment (Matsumoto 2007), and one study
compared FFP plus heparin with heparin alone (Yannaki 2012). One
study compared antithrombin III (1000 units twice daily from day
one till day 14 post-transplant) plus heparin with heparin alone
(Jung 2005). The three-arm study compared heparin (100 units/
kg/day) with enoxaparin (20 mg/day) and prostaglandin E1 (PGE1)
(500 microgram/kg/day) (Demuynck 1995). No trial investigated the
eKects of danaparoid.
Outcomes
Thirteen studies reported the incidence of hepatic veno-occlusive
disease (VOD) as an outcome measure (Attal 1992; Brown 1998;
Corbacioglu 2012; Demuynck 1995; Essell 1998; Jung 2005; Lee
1996; Marsa-Vila 1991; Matsumoto 2007; Ohashi 2000; Park 2002;
Ruutu 2002; Yannaki 2012). One study did not report the incidence
of hepatic VOD, but frequencies of individual symptom or sign
of hepatic VOD in participants, including hyperbilirubinaemia,
hepatic enlargement, right upper quadrant abdominal pain,
ascites, and weight gain (Or 1996). Five studies reported overall
survival (Attal 1992; Corbacioglu 2012; Essell 1998; Park 2002;
Ruutu 2002). Six studies reported all-cause mortality (Brown 1998;
Corbacioglu 2012; Essell 1998; Ohashi 2000; Park 2002; Ruutu 2002)
and nine studies reported mortality attributable to hepatic VOD
(Attal 1992; Brown 1998; Corbacioglu 2012; Demuynck 1995; Essell
1998; Jung 2005; Ohashi 2000; Park 2002; Ruutu 2002). None of
the 14 included studies reported quality of life of participants.
Eleven studies reported adverse events (Attal 1992; Brown 1998;
Corbacioglu 2012; Demuynck 1995; Essell 1998; Jung 2005; Lee
1996; Ohashi 2000; Or 1996; Park 2002; Ruutu 2002), which were
mainly bleeding complications.
Excluded studies
We excluded one study aJer examining the full text of the
published reports (Characteristics of excluded studies). This study
was evaluating treatment of hepatic VOD instead of prophylaxis
(Carbacioglu 2004).
Risk of bias in included studies
The distribution of risk of bias in diKerent aspects of the included
studies is shown in Figure 2 and Figure 3.
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Figure 2.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
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Figure 3.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Figure 3.   (Continued)
 
Allocation
Two studies used computer-generated random sequence for
randomisation (Attal 1992; Corbacioglu 2012). The sequence was
unknown to study physicians and communicated via telephone
(Attal 1992) or managed by a central data manager (Corbacioglu
2012). These were considered adequate randomisation with
adequate concealment and at low risk of bias. Another study
used randomly assorted allocation cards stored in sealed, opaque,
numbered envelops and that was also considered at low risk of
bias (Essell 1998). The other studies did not describe random
sequence generation or allocation concealment and were therefore
considered to have unclear risk of bias (Brown 1998; Demuynck
1995; Jung 2005; Lee 1996; Marsa-Vila 1991; Matsumoto 2007;
Ohashi 2000; Or 1996; Park 2002; Ruutu 2002; Yannaki 2012).
Blinding
Participants, study personnel and outcome assessors were blinded
to treatment allocation in two studies (Essell 1998; Or 1996). These
were considered to have low risk of bias. Participants and study
personnel were also blinded in another study (Brown 1998), but
it was unclear whether outcome assessors were also blinded in
this study. The other studies did not attempt to blind either the
participants or study personnel and therefore were considered to
have high risk of bias (Attal 1992; Corbacioglu 2012; Demuynck
1995; Jung 2005; Lee 1996; Marsa-Vila 1991; Matsumoto 2007;
Ohashi 2000; Park 2002; Ruutu 2002; Yannaki 2012). Outcome
assessors were also not blinded in two of these studies (Attal 1992;
Corbacioglu 2012). It was unclear whether outcome assessors for
the remaining nine studies were blinded or not (Demuynck 1995;
Jung 2005; Lee 1996; Marsa-Vila 1991; Matsumoto 2007; Ohashi
2000; Park 2002; Ruutu 2002; Yannaki 2012).
Incomplete outcome data
Outcome data were complete in five studies (Attal 1992; Brown
1998; Or 1996; Park 2002; Yannaki 2012). Dropouts occurred in only
one participant in one study (Essell 1998), and one participant each
in treatment and control groups in another study (Ruutu 2002).
These were considered unlikely to cause attrition bias. Dropouts
occurred in more than 30% of participants in one study which
were considered to have high risk of bias (Corbacioglu 2012). In
two other studies, the dropouts were uneven among the treatment
and control groups and were considered to have high risk of
bias (Matsumoto 2007; Ohashi 2000). Dropouts were not described
in the remaining studies (Demuynck 1995; Jung 2005; Lee 1996;
Marsa-Vila 1991) and the risk of bias was unclear.
Selective reporting
The trial protocols were not available for most included studies
to judge whether there might have been selective reporting of
outcomes (Attal 1992; Brown 1998; Demuynck 1995; Essell 1998;
Jung 2005; Lee 1996; Marsa-Vila 1991; Matsumoto 2007; Ohashi
2000; Or 1996; Park 2002; Ruutu 2002; Yannaki 2012). These studies
were therefore considered to have unclear risk of bias in this
respect. One study (Corbacioglu 2012) was registered with a brief
protocol available and all relevant outcomes were reported and
hence considered to have low risk of bias.
Other potential sources of bias
In one study (Attal 1992), diagnostic criteria or diagnostic
evaluation for hepatic VOD was not uniformly applied to all
participants and therefore might cause bias. In seven studies (Attal
1992; Brown 1998; Essell 1998; Matsumoto 2007; Ohashi 2000;
Or 1996; Park 2002), some of the baseline characteristics of the
treatment and the control groups were not comparable and might
introduce bias. In five studies (Demuynck 1995; Jung 2005; Lee
1996; Marsa-Vila 1991; Yannaki 2012), information was not available
to judge whether the baseline characteristics of the treatment and
the control groups were comparable. In three studies (Brown 1998;
Essell 1998; Matsumoto 2007), co-interventions were diKerent
between the treatment and the control groups and this might
introduce bias. In five studies (Demuynck 1995; Jung 2005; Lee
1996; Marsa-Vila 1991; Yannaki 2012), information was not available
to judge whether co-intervention was comparable between the
treatment and the control groups.
E?ects of interventions
See: Summary of findings for the main comparison Summary
of findings: Ursodeoxycholic acid versus placebo or no treatment;
Summary of findings 2 Summary of findings: Heparin versus
no treatment; Summary of findings 3 Summary of findings:
Low molecular weight heparin versus placebo or no treatment;
Summary of findings 4 Summary of findings: Defibrotide versus
no treatment; Summary of findings 5 Summary of findings:
Glutamine versus placebo; Summary of findings 6 Summary of
findings: Fresh frozen plasma versus no treatment; Summary of
findings 7 Summary of findings: Antithrombin III plus heparin
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versus heparin alone; Summary of findings 8 Summary of
findings: Heparin versus low molecular weight heparin; Summary
of findings 9 Summary of findings: Heparin versus prostaglandin
E1; Summary of findings 10 Summary of findings: Low molecular
weight heparin versus prostaglandin E1
All data presented were extracted from published reports.
Comparison 1: Ursodeoxycholic acid versus placebo or no
treatment
Two included trials compared ursodeoxycholic acid with placebo
(Essell 1998; Ruutu 2002). One trial compared ursodeoxycholic
acid with no treatment (Ohashi 2000) and one trial compared
ursodeoxycholic acid plus heparin with heparin alone (Park 2002).
We analysed these four trials with 612 participants together under
this comparison.
Primary outcomes
Incidence of hepatic VOD
Four included studies (Essell 1998; Ohashi 2000; Park 2002; Ruutu
2002) reported this outcome. One study (Essell 1998) had one
participant absent from the control group, one study (Ohashi 2000)
had four participants absent from the treatment group, one study
(Ruutu 2002) had one participant each in the treatment and the
control group dropped out or with missing data, and they were
assumed not to have developed hepatic VOD. The pooled result
showed that ursodeoxycholic acid reduced the risk of development
of hepatic VOD compared to control treatment (risk ratio (RR) 0.60,
95% confidence interval (CI) 0.40 to 0.88, P = 0.01, 4 trials with
612 participants) (Analysis 1.1; Figure 4). The number needed to
treat for an additional beneficial outcome (NNTB) was 15 (95% CI
7 to 50). However, there was substantial heterogeneity among the
studies in this outcome (I2 = 59%; Chi2 test P = 0.06), which might
be related to diKerences in the participants and the treatment
regimen. The missing data might also result in bias of the result. As
a sensitivity analysis, a random-eKects meta-analysis showed there
was no evidence of a diKerence in the incidence of hepatic VOD
between ursodeoxycholic acid and control treatment (RR 0.55, 95%
CI 0.28 to 1.08, P = 0.08).
 
Figure 4.   Forest plot of comparison: 1 Ursodeoxycholic acid versus placebo or no treatment, outcome: 1.1 Incidence
of hepatic VOD.
 
Overall survival
The pooled result of three studies (Essell 1998; Park 2002; Ruutu
2002) showed no significant diKerence in overall survival between
the treatment and the control groups (hazard ratio (HR) 0.83, 95%
CI 0.59 to 1.18, P = 0.30, 3 of 4 trials with 77.5% of participants)
(Analysis 1.2). There was moderate heterogeneity among the
trials in this outcome (I2 = 33%, Chi2 test P = 0.22). One study
(Ruutu 2002) had one participant in the treatment group who died
and one participant in the control group who dropped out, and
were excluded from the survival data. One study did not provide
suKicient information to be included in the meta-analysis on overall
survival (Ohashi 2000). However, this study commented that the
survival curves did not diKer significantly between the treatment
and the control groups.
Secondary outcomes
All-cause mortality
All four included studies (Essell 1998; Ohashi 2000; Park 2002; Ruutu
2002) reported all-cause mortality at 100 days post-transplant. One
study (Essell 1998) had one participant missing from the control
group, one study (Ohashi 2000) had three participants missing
from the treatment group and another study (Ruutu 2002) had one
participant in the control group dropped out or with missing data,
and they were assumed to be surviving. The pooled results showed
that ursodeoxycholic acid reduced all-cause mortality at 100 days
post-transplant compared to control treatment (RR 0.70, 95% CI
0.50 to 0.99, P = 0.04, all 4 trials with all 612 participants) (Analysis
1.3). The NNTB was 17 (95% CI 8 to 431). There was no important
heterogeneity among the trials in this outcome (I2 = 0%, Chi2 test P
= 0.46). However, the missing data might result in bias of the result.
Mortality attributable to hepatic VOD
The pooled results of all four studies (Essell 1998; Ohashi
2000; Ruutu 2002; Park 2002) showed that ursodeoxycholic acid
reduced mortality attributable to hepatic VOD compared to control
treatment (RR 0.27, 95% CI 0.09 to 0.87, P = 0.03, all 4 trials with
all 612 participants) (Analysis 1.4). The NNTB was 34 (95% CI 16 to
220). There was no important heterogeneity among the trials in this
outcome (I2 = 0%, Chi2 test P = 0.81). One study (Essell 1998) had
one participant absent from the control group, one study (Ohashi
2000) had three participants absent from the treatment group and
another study (Ruutu 2002) had one participant in the control group
dropped out or with missing data, and they were assumed to be
surviving. The missing data might result in bias of the result.
Quality of life
None of the four trials (Essell 1998; Ohashi 2000; Park 2002; Ruutu
2002) reported this outcome.
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Frequency of adverse events
In three studies (Essell 1998; Ohashi 2000; Ruutu 2002), none
of the participants in either the treatment or the control
groups experienced any adverse event. Outcomes regarding one
participant in the control group in one study (Essell 1998) and two
participants in the treatment group in another study (Ohashi 2000)
were missing and they were assumed to have no adverse events
due to treatment. The missing data might result in bias of the
result. In the study comparing ursodeoxycholic acid plus heparin
with heparin alone (Park 2002), eight participants in the treatment
group and nine participants in the control group experienced
bleeding or prolonged activated partial thromboplastin time
(APTT) necessitating withdrawal of treatment. There was no
significant diKerence in the frequency of adverse events between
the treatment and the control groups (RR 0.90, 95% CI 0.37 to 2.22,
P = 0.82, 1 trial with all 165 participants) (Analysis 1.5).
Comparison 2: Heparin versus no treatment
Two included studies with 259 participants compared heparin
alone with no treatment (Attal 1992; Marsa-Vila 1991).
Primary outcomes
Incidence of hepatic VOD
The pooled result of the two studies (Attal 1992; Marsa-Vila 1991)
showed no significant diKerence in the incidence of hepatic VOD
between the treatment and the control groups (RR 0.47, 95% CI
0.18 to 1.26, P = 0.13, both trials with all 259 participants) (Analysis
2.1; Figure 5). There was considerable heterogeneity between the
two studies (I2 = 80%, Chi2 test P = 0.03), which might be due to
diKerences in participants and the type of transplant performed. As
a sensitivity analysis, a random-eKects meta-analysis also showed
no evidence of a diKerence in the incidence of hepatic VOD between
the treatment and the control groups (RR 0.72, 95% CI 0.04 to 13.19,
P = 0.82).
 
Figure 5.   Forest plot of comparison: 2 Heparin versus no treatment, outcome: 2.1 Incidence of hepatic VOD.
 
Overall survival
One study (Attal 1992) with 62.2% of all participants reported no
significant diKerence in overall survival between the treatment
group (92.6%) and the control group (88.7%) (Analysis 2.2).
However, no suKicient information was available for re-analysis.
The other study did not report overall survival (Marsa-Vila 1991).
Secondary outcomes
All-cause mortality
One study (Attal 1992) reported all-cause mortality at 100 days
post-transplant and showed no significant diKerence between the
treatment and the control groups (RR 0.66, 95% CI 0.25 to 1.76, P =
0.41, 1 of 2 trials with 62.2% of all participants) (Analysis 2.3). The
other study did not report all-cause mortality (Marsa-Vila 1991).
Mortality attributable to hepatic VOD
One study (Attal 1992) reported mortality attributable to hepatic
VOD and showed no significant diKerence between the treatment
and the control groups (RR 0.28, 95% CI 0.06 to 1.32, P = 0.11, 1 of 2
trials with 62.2% of all participants) (Analysis 2.4). The other study
did not report this outcome (Marsa-Vila 1991).
Quality of life
Neither trial (Attal 1992; Marsa-Vila 1991) reported this outcome.
Frequency of adverse events
One study reported that three participants in the treatment group
experienced minor gastrointestinal bleeding (Attal 1992). None of
the participants in the control group experienced this. There was no
significant diKerence in the frequency of adverse events between
the treatment and the control groups (RR 6.91, 95% CI 0.36 to
131.75, P = 0.20, 1 of 2 trials with 62.2% of all participants) (Analysis
2.5). The other study did not report adverse event (Marsa-Vila 1991).
Comparison 3: Low molecular weight heparin versus placebo
or no treatment
Two studies with 106 participants compared low molecular weight
heparin with placebo or no treatment, including one study
comparing nadroparin with no treatment (Lee 1996) and one study
comparing enoxaparin with placebo (Or 1996).
Primary outcomes
Incidence of hepatic VOD
One study (Lee 1996) reported no significant diKerence in the
incidence of hepatic VOD between the treatment and the control
groups (RR 0.27, 95% CI 0.06 to 1.18, P = 0.08, 1 of 2 trials with 42.5%
of all participants) (Analysis 3.1). The other study (Or 1996) did not
report the incidence of hepatic VOD, but reported frequencies of
hyperbilirubinaemia, hepatic enlargement, right upper quadrant
abdominal pain, ascites, and weight gain.
Overall survival
Neither study (Lee 1996; Or 1996) reported overall survival of
participants.
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Secondary outcomes
All-cause mortality
Neither study (Lee 1996; Or 1996) reported all-cause mortality of
participants.
Mortality attributable to hepatic VOD
Neither study (Lee 1996; Or 1996) reported mortality attributable to
hepatic VOD.
Quality of life
Neither study (Lee 1996; Or 1996) reported quality of life of
participants.
Frequency of adverse events
One study (Or 1996) reported withdrawal of treatment because
of bleeding in five participants in the treatment group and eight
participants in the control group, which represented no significant
diKerence between the two groups (RR 0.74, 95% CI 0.27 to 2.00,
P = 0.55, 1 of 2 trials with 57.5% of all participants) (Analysis 3.2).
The other study stated that there was no increase in haemorrhagic
complications in the treatment group compared with the control
group, without providing numerical data (Lee 1996).
Comparison 4: Defibrotide versus no treatment
One included study with 360 participants compared defibrotide
with no treatment (Corbacioglu 2012).
Primary outcomes
Incidence of hepatic VOD
The included study (Corbacioglu 2012) revealed lower frequency
of hepatic VOD in the treatment group (12.2%) compared with
the control group (19.6%) but the diKerence was not statistically
significant (RR 0.62, 95% CI 0.38 to 1.02, P = 0.06, 1 trial with all
360 participants) (Analysis 4.1). One participant in the treatment
group and three participants in the control group dropped out
and were assumed not to have developed VOD. This study also
reported subgroup analyses for incidence of hepatic VOD. There
was no statistically significant diKerence in the incidence of hepatic
VOD between the treatment and the control groups in infants and
children (RR 0.70, 95% CI 0.41 to 1.19, P = 0.19, 1 trial with 75.8%
of all participants) (Analysis 4.2) or in adolescents (RR 0.35, 95% CI
0.10 to 1.22, P = 0.10, 1 trial with 23.1% of all participants) (Analysis
4.2). There was also no statistically significant diKerence in the
incidence of hepatic VOD between the treatment and the control
groups in participants with osteopetrosis (RR 0.21, 95% CI 0.03 to
1.43, P = 0.11, 1 trial with 3.6% of all participants) (Analysis 4.3) or in
participants without osteopetrosis (RR 0.67, 95% CI 0.40 to 1.11, P =
0.12, 1 trial with 95.3% of all participants) (Analysis 4.3). There was
no statistically significant diKerence in the incidence of hepatic VOD
between the treatment and the control groups in participants who
received allogeneic transplant (RR 0.58, 95% CI 0.32 to 1.04, P = 0.07,
1 trial with 66.4% of all participants) (Analysis 4.4) or in participants
who received autologous transplant (RR 0.73, 95% CI 0.30 to 1.77,
P = 0.43, 1 trial with 30% of all participants) (Analysis 4.4). There
was no evidence of diKerences in the eKects of defibrotide between
diKerent age groups (I2 = 0%, Chi2 test P = 0.32), between the groups
with or without osteoporosis (I2 = 21.5%, Chi2 test P = 0.26), or
between diKerent types of transplants (I2 = 0%, Chi2 test P = 0.67)
Overall survival
This study (Corbacioglu 2012) showed no significant diKerence in
the overall survival between the treatment and the control groups
(HR 1.04, 95% CI 0.54 to 2.02, P = 0.90, 1 trial with 98.9% of
all participants) (Analysis 4.5). One participant in the treatment
group and three participants in the control group dropped out and
were excluded from survival analysis. Many participants had short
follow-up and only 48.1% of participants had outcome data by the
end of follow-up at 180 days post-transplant. The missing data
might cause bias in the result.
Secondary outcomes
All-cause mortality
There was no significant diKerence in all-cause mortality at 100
days post-transplant between the treatment and the control groups
(RR 1.05, 95% CI 0.56 to 1.97, P = 0.89, 1 trial with all 360
participants) (Analysis 4.6). One participant in the treatment group
and three participants in the control group dropped out and were
assumed to be surviving.
Mortality attributable to hepatic VOD
There was no significant diKerence in mortality attributable to
hepatic VOD between the treatment and the control groups (RR
0.40, 95% CI 0.13 to 1.24, P = 0.11, 1 trial with all 360 participants)
(Analysis 4.7). One participant in the treatment group and three
participants in the control group dropped out and were assumed to
be surviving.
Quality of life
This study (Corbacioglu 2012) did not report quality of life of
participants.
Frequency of adverse events
This study reported significantly more adverse events related to
defibrotide in the treatment group compared with the control
group (RR 18.79, 95% CI 1.10 to 320.45, P = 0.04, 1 trial with all
360 participants) (Analysis 4.8). There were nine adverse events
related to defibrotide in the treatment group but no adverse event
in the control group. Reported adverse events of participants
who had received defibrotide in this study included coagulopathy,
gastrointestinal disorders, haemorrhage and microangiopathy.
There was no significant diKerence in the frequency of severe
adverse events between the treatment group (three participants)
and the control group (no participant) (RR 6.92, 95% CI 0.36 to
133.07, P = 0.20, 1 trial with all 360 participants) (Analysis 4.9). There
was also no significant diKerence in the frequency of haemorrhage
between the treatment group (39 participants) and the control
group (37 participants) (RR 1.04, 95% CI 0.70 to 1.55, P = 0.84, 1 trial
with all 360 participants) (Analysis 4.10).
Comparison 5: Glutamine versus placebo
One included study with 34 participants compared glutamine with
placebo (Brown 1998).
Primary outcomes
Incidence of hepatic VOD
None of the 34 participants in this study (Brown 1998) developed
hepatic VOD.
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Overall survival
This study (Brown 1998) did not report overall survival of
participants.
Secondary outcomes
All-cause mortality
There was no significant diKerence in all-cause mortality at 100
days post-transplant between the treatment and the control groups
(RR 0.30, 95% CI 0.01 to 6.84, P = 0.45, 1 trial with all 34 participants)
(Analysis 5.1).
Mortality attributable to hepatic VOD
There was no death attributable to VOD in this study (Brown 1998).
Quality of life
This study (Brown 1998) did not report quality of life of participants.
Frequency of adverse events
One participant who received glutamine had a sensation of
abdominal fullness. None of the participants who received placebo
experienced an adverse event. There was no significant diKerence
in the frequency of adverse events between the two groups (RR
2.68, 95% CI 0.12 to 61.58, P = 0.54, 1 trial with all 34 participants)
(Analysis 5.2).
Comparison 6: Fresh frozen plasma versus no treatment
One included study compared fresh frozen plasma with no
treatment (Matsumoto 2007) and one study compared fresh frozen
plasma plus heparin with heparin alone (Yannaki 2012). We
analysed these two trials with 379 participants together.
Primary outcomes
Incidence of hepatic VOD
The pooled result of the two included studies (Matsumoto 2007;
Yannaki 2012) showed no significant diKerence in the incidence of
hepatic VOD between the treatment and the control groups (RR
0.66, 95% CI 0.20 to 2.17, P = 0.50, 2 trials of all 379 participants)
(Analysis 6.1). There was moderate heterogeneity between the
studies in this outcome (I2 = 47%; Chi2 test P = 0.17), which might
be related to diKerences in the participants and the treatment
regimen. One study (Matsumoto 2007) had one participant in
the treatment group and three participants in the control group
dropped out, and they were assumed not to have developed VOD.
The missing data might cause bias in the result.
Overall survival
The included studies (Matsumoto 2007; Yannaki 2012) did not
report overall survival of participants.
Secondary outcomes
All-cause mortality
The included studies (Matsumoto 2007; Yannaki 2012) did not
report all-cause mortality of participants.
Mortality attributable to hepatic VOD
The included studies (Matsumoto 2007; Yannaki 2012) did not
report mortality attributable to hepatic VOD of participants.
Quality of life
The included studies (Matsumoto 2007; Yannaki 2012) did not
report quality of life of participants.
Frequency of adverse events
The included studies (Matsumoto 2007; Yannaki 2012) did not
report adverse events.
Comparison 7: Antithrombin III plus heparin versus heparin
alone
One included study with 30 participants compared antithrombin III
plus heparin with heparin alone (Jung 2005).
Primary outcomes
Incidence of hepatic VOD
This study (Jung 2005) reported no significant diKerence in the
incidence of hepatic VOD between the treatment and the control
groups (RR 0.13, 95% CI 0.01 to 2.15, P = 0.15, 1 trial with all 30
participants) (Analysis 7.1).
Overall survival
This study (Jung 2005) did not report overall survival of
participants.
Secondary outcomes
All-cause mortality
This study (Jung 2005) did not report all-cause mortality of
participants.
Mortality attributable to hepatic VOD
None of the participants in this study (Jung 2005) died of hepatic
VOD.
Quality of life
This study (Jung 2005) did not report quality of life of participants.
Frequency of adverse events
This study (Jung 2005) reported bleeding complications in one
participant in the treatment group and four participants in the
control group, which represented no significant diKerence between
the two groups (RR 0.29, 95% CI 0.04 to 2.27, P = 0.24, 1 trial with all
30 participants) (Analysis 7.2).
Comparison 8: Heparin versus low molecular weight heparin
One included study compared heparin (47 participants) with
enoxaparin (46 participants) (Demuynck 1995).
Primary outcomes
Incidence of hepatic VOD
This study (Demuynck 1995) reported no significant diKerence in
the incidence of hepatic VOD between the two treatment groups
(RR 1.96, 95% CI 0.80 to 4.77, P = 0.14, 1 trial with 93 participants)
(Analysis 8.1).
Overall survival
This study (Demuynck 1995) did not report overall survival.
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Secondary outcomes
All-cause mortality
This study (Demuynck 1995) did not report all-cause mortality of
participants.
Mortality attributable to hepatic VOD
This study (Demuynck 1995) reported no significant diKerence in
mortality attributable to hepatic VOD between the two treatment
groups (RR 2.94, 95% CI 0.12 to 70.30, P = 0.51, 1 trial with 93
participants) (Analysis 8.2).
Quality of life
This study (Demuynck 1995) did not report quality of life of
participants.
Frequency of adverse events
This study (Demuynck 1995) reported bleeding complications in
six participants in the heparin group and seven participants in
the enoxaparin group, which represented no significant diKerence
between the two groups (RR 0.84, 95% CI 0.30 to 2.31, P = 0.73, 1
trial with 93 participants) (Analysis 8.3).
Comparison 9: Heparin versus prostaglandin E1
One included study compared heparin (47 participants) with
prostaglandin E1 (47 participants) (Demuynck 1995).
Primary outcomes
Incidence of hepatic VOD
This study (Demuynck 1995) reported no significant diKerence in
the incidence of hepatic VOD between the two treatment groups
(RR 1.20, 95% CI 0.58 to 2.50, P = 0.63, 1 trial with 94 participants)
(Analysis 9.1).
Overall survival
This study (Demuynck 1995) did not report overall survival.
Secondary outcomes
All-cause mortality
This study (Demuynck 1995) did not report all-cause mortality of
participants.
Mortality attributable to hepatic VOD
This study (Demuynck 1995) reported no significant diKerence in
mortality attributable to hepatic VOD between the two treatment
groups (RR 0.50, 95% CI 0.05 to 5.33, P = 0.57, 1 trial with 94
participants) (Analysis 9.2).
Quality of life
This study (Demuynck 1995) did not report quality of life of
participants.
Frequency of adverse events
This study (Demuynck 1995) reported bleeding complications in
six participants who received heparin. Fourteen participants who
received prostaglandin E1 experienced serious adverse events,
including bleeding in two, musculoskeletal pain in six, hypotension
in one, and other adverse events in five participants. There was no
significant diKerence in the frequency of adverse events between
the two groups (RR 0.43, 95% CI 0.18 to 1.02, P = 0.06, 1 trial with 94
participants) (Analysis 9.3).
Comparison 10: Low molecular weight heparin versus
prostaglandin E1
One included study compared enoxaparin (46 participants) with
prostaglandin E1 (47 participants) (Demuynck 1995).
Primary outcomes
Incidence of hepatic VOD
This study (Demuynck 1995) reported no significant diKerence in
the incidence of hepatic VOD between the two treatment groups
(RR 0.61, 95% CI 0.24 to 1.55, P = 0.30, 1 trial with 93 participants)
(Analysis 10.1).
Overall survival
This study (Demuynck 1995) did not report overall survival.
Secondary outcomes
All-cause mortality
This study (Demuynck 1995) did not report all-cause mortality of
participants.
Mortality attributable to hepatic VOD
This study (Demuynck 1995) reported no significant diKerence in
mortality attributable to hepatic VOD between the two treatment
groups (RR 0.20, 95% CI 0.01 to 4.14, P = 0.30, 1 trial with 93
participants) (Analysis 10.2).
Quality of life
This study (Demuynck 1995) did not report quality of life of
participants.
Frequency of adverse events
This study reported bleeding complications in seven participants
who received enoxaparin. Fourteen participants who received
prostaglandin E1 experienced serious adverse events, including
bleeding in two, musculoskeletal pain in six, hypotension in one,
and other adverse events in five participants. There was no
significant diKerence in the frequency of adverse events between
the two groups (RR 0.51, 95% CI 0.23 to 1.15, P = 0.10, 1 trial with 93
participants) (Analysis 10.3).
Reporting bias
Since we found fewer than 10 studies for any comparison, we could
not reliably assess publication bias and did not produce funnel
plots for any outcome.
D I S C U S S I O N
Summary of main results
Fourteen randomised controlled trials (RCTs) evaluated
prophylactic therapies for hepatic veno-occlusive disease (VOD)
in haematopoietic stem cell transplant (HSCT) recipients. Eleven
trials compared active treatments with placebo or no treatment,
including ursodeoxycholic acid (three trials), heparin (two trials),
low molecular weight heparin (two trials), defibrotide (one
trial), glutamine (one trial), fresh frozen plasma (one trial), and
antithrombin III (one trial). One trial compared ursodeoxycholic
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acid plus heparin with heparin alone and we meta-analysed this
trial together with the other three trials on ursodeoxycholic acid.
One trial compared fresh frozen plasma plus heparin with heparin
alone and we meta-analysed this trial together with the other
trial on fresh frozen plasma. One trial compared heparin with low
molecular weight heparin and prostaglandin E1 and we conducted
pair-wise comparisons.
The results showed that ursodeoxycholic acid, compared with
placebo or no treatment, was associated with a reduction in the
incidence of hepatic VOD, all-cause mortality, and mortality due to
hepatic VOD (four RCTs; 612 participants). However, the estimates
of eKect size were imprecise with wide confidence intervals.
There was also substantial heterogeneity in the primary outcome.
Sensitivity analysis by re-analysis of the primary outcome of the
incidence of hepatic VOD using a random-eKects model showed
no significant diKerence between the treatment and the control
groups. All other RCTs on other prophylactic therapies failed to
show eKicacy in any of the outcomes considered.
In most studies, there was no evidence of a diKerence between
the treatment and the control groups in the frequency of adverse
events. One trial showed that participants who received defibrotide
had more adverse events compared with the control group
who did not receive defibrotide for prophylaxis. However, the
estimate of the diKerence was grossly imprecise. Reported adverse
events of defibrotide included coagulopathy, gastrointestinal
disorders, haemorrhage and microangiopathy. However, there was
no evidence of a diKerence in the frequency of severe adverse
events or haemorrhage.
Overall completeness and applicability of evidence
Many diKerent prophylactic therapies were tested in RCTs.
However, most trials failed to show eKicacies of these therapies
when compared to placebo or no treatment, including trials on
heparin, low molecular weight heparin, glutamine, fresh frozen
plasma, and antithrombin III. There was no evidence of diKerences
between Prostaglandin E1, heparin or low molecular weight
heparin in any outcomes considered. In the RCT of defibrotide
compared with no treatment, there was some discrepancy in the
analysis and interpretation of results between the primary study
report and our systematic review. The authors of the study used
competing risk analysis for the cumulative incidence of hepatic
VOD and found that there was a borderline statistically significant
diKerence between the treatment and the control groups, with an
absolute risk diKerence of 7.7% in favour of the treatment group (P =
0.0488). However, they reported statistically non-significant results
when they analysed the data using the log rank test (P = 0.05). Of
note is that the authors of the study excluded four randomised
participants in their analyses and therefore these analyses were
not genuinely intention-to-treat. Our re-analysis based on the
published data assuming the four excluded participants did not
develop hepatic VOD showed no evidence of a diKerence in the
incidence of hepatic VOD between the treatment group (12.2%)
and the control group (19.6%). The eKicacy, if any, of defibrotide
in preventing hepatic VOD appears to be modest, and the benefit
was uncertain. The trial might have insuKicient statistical power
to detect a significant diKerence between the groups and further
large studies are needed to clarify the eKicacy of defibrotide for
prophylaxis of hepatic VOD.
We found that the only agent that is possibly eKective in preventing
hepatic VOD in HSCT recipients is ursodeoxycholic acid, which
resulted in a relative risk for hepatic VOD of 0.6, with an absolute
risk diKerence of 7% and a number needed to treat for an additional
beneficial outcome (NNTB) of 15. However, the included studies
were small and the eKect size estimates were imprecise. There
was significant heterogeneity among the included studies in terms
of participant characteristics and treatment regimens. Re-analysis
of the primary outcome using a random-eKects model yielded
no significant diKerence in the incidence of hepatic VOD between
the treatment and the control groups, raising further uncertainly
about the eKicacy of ursodeoxycholic acid. The dosing regimen of
ursodeoxycholic acid and the duration of prophylaxis were variable
among the trials. It remains uncertain what the optimal regimen
may be, and whether ursodeoxycholic acid benefits all HSCT
recipients or only certain groups . Moreover, the cost eKectiveness
of ursodeoxycholic acid as prophylaxis for hepatic VOD remains to
be determined.
On the other hand, due to inadequate sample size in the existing
trials, the failure to show clinical benefits of many prophylactic
regimens may be false negative results. Therefore, the potential
benefits of diKerent prophylactic therapies in HSCT recipients
cannot be entirely excluded based on the currently available
evidence. Further trials of adequate sample size are needed to
clarify the role of diKerent prophylactic agents.
In addition, the included trials were of inadequate sample sizes
to assess rare adverse events or to determine whether there are
genuine diKerences in the frequency of adverse events among
treatment groups.
Quality of the evidence
Apart from scarcity of RCTs and inadequate statistical power to
detect diKerences between the treatment and the control groups,
the trials included in the current review were prone to bias
in diKerent aspects. We considered that none of the included
studies was at low risk of bias in all aspects assessed. In many
included studies, the treatment and the control groups were not
comparable at baseline, which casts doubt on the success of
randomisation and increases the probability of confounding. Many
included studies did not report the random sequence generation or
allocation concealment which are important to minimise selection
bias. Most included studies failed to blind the participants and
personnel which might introduce performance bias. Some trials
had significant dropouts and were prone to attrition bias. Trial
protocols were not available in most trials and it was uncertain
whether there was reporting bias in these RCTs.
Potential biases in the review process
There are potential biases at both the study level and the review
level. The risk of bias at the study level is detailed above in the
section Risk of bias in included studies. At the review level, there
is possible reporting bias, as we only searched major English
electronic databases and therefore non-English literature might
be under-represented and missed in the review. Publication bias
was also possible. However, the number of included studies was
too small for formal evaluation and testing for publication bias. In
addition, we only included RCTs in the review and serious or rare
adverse events, or both, might have been missed.
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Agreements and disagreements with other studies or
reviews
There is a systematic review on the use of ursodeoxycholic acid
for prophylaxis of VOD in HSCT recipients (Tay 2007). This review
included four RCTs and two historically controlled studies, with a
total of 824 participants. The RCTs included were the same as in
our review, with similar conclusions. Ursodeoxycholic acid resulted
in a lower incidence of hepatic VOD compared with placebo or no
treatment (RR 0.34; 95% CI 0.17 to 0.66, P = 0.002, 3 studies). As in
our findings, overall survival showed no evidence of a diKerence
between the treatment and the control groups.
There is also a systematic review on the use of anticoagulants for
prophylaxis of hepatic VOD in HSCT recipients (Imran 2006). Three
RCTs and nine cohort studies with a total of 2782 participants were
included in this review. The RCTs included were the same as in our
review, and evaluate heparin (two RCTs) or enoxaparin (one RCT).
The pooled result of all studies showed no evidence of a diKerence
in the incidence of hepatic VOD between the treatment and the
control groups (RR 0.90; 95% CI 0.62 to 1.29, P = 0.55, 12 studies).
This is consistent with our review which includes RCTs only.
There is another systematic review evaluating defibrotide for
prophylaxis of hepatic VOD in HSCT recipients (Zhang 2012). This
review included one RCT, four cohort studies and eight case
series with a total of 1230 participants. It included the same
RCT (Corbacioglu 2012) as in our review. The review found that
the overall mean incidence of VOD in participants who received
defibrotide was lower compared with those who did not receive
defibrotide (4.7% versus 13.7%, RR 0.47, 95% CI 0.31 to 0.73, P =
0.0006, 5 studies). However, the authors made similar comments to
ours that the methodological weaknesses of the studies precluded
making generalisable conclusions and that large RCTs were needed
for further confirmation.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
There is evidence of low quality that ursodeoxycholic acid might
be eKective in reducing the incidence of hepatic veno-occlusive
disease (VOD), overall mortality and mortality due to hepatic VOD
in haematopoietic stem call transplant (HSCT) recipients. However,
it is uncertain whether ursodeoxycholic acid benefits all HSCT
recipients or only a subset of high-risk people. The optimal regimen
of ursodeoxycholic acid for prophylaxis of hepatic VOD has not been
well defined. Ursodeoxycholic acid is not associated with excess
adverse events compared with control groups in randomised
controlled trials (RCTs). However, the small number of participants
included in the RCTs precludes firm conclusion on rare adverse
events. There is insuKicient evidence to support the use of other
prophylactic regimens, including heparin, low molecular weight
heparin, defibrotide, glutamine, fresh frozen plasma, antithrombin
III, or prostaglandin E1.
Implications for research
The existing trials are of small size and low methodological
quality. Further high-quality RCTs of larger sample size are
needed to assess the eKectiveness of ursodeoxycholic acid for
prophylaxis of hepatic VOD in HSCT recipients to validate its
eKectiveness, and to determine the group of people most likely
to benefit and the optimal dosage regimen. Other therapeutic
options such as defibrotide, heparin, low molecular weight heparin,
glutamine, fresh frozen plasma and antithrombin III, alone or
in combination with ursodeoxycholic acid also need more high-
quality RCTs of larger sample size for further evaluation. Adequate
random sequence generation, allocation concealment, blinding of
participants, clinicians and outcome assessors are essential.
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of deep vein thrombosis, non-standard conditioning regimen, mismatched allogeneic stem cell trans-
plant, matched unrelated allogeneic transplant• Number of participants (intervention group : control group): 81 : 80• Number of men (intervention group : control group): 55 : 47• Age of participants (intervention group : control group): mean (SD) in years: 36.3 (14.4) : 35.9 (14)• Underlying diseases: Intervention group: AML (17), ALL (15), CML (18), myeloma (16), lymphoma (13),
aplasia (2); Control group: AML (15), ALL (16), CML (12), myeloma (17), lymphoma (16), aplasia (4)• Previous treatments (intervention group : control group): information not available• Pre-existing liver dysfunction (intervention group : control group): AST > 40 IU/L: 10 : 7; Bilirubin > 19
micromol/L: 2 : 5
Attal 1992 
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• Previous history of hepatic VOD (intervention group : control group): 0 : 0• Performance status before transplant (intervention group : control group): information not available• Type of transplant: Intervention group: allogeneic (39), syngeneic (1), autologous (41); Control group:
allogeneic (38), syngeneic (1), autologous (41)• Donor (intervention group : control group): allogeneic (39), syngeneic (1), autologous (41); Control
group: allogeneic (38), syngeneic (1), autologous (41)• HLA disparity (intervention group : control group): information not available• Stem cell source (intervention group : control group): all participants received bone marrow• Stem cell manipulation (intervention group : control group): no manipulation for all participants• Conditioning regimen: Intervention group: CY-TBI (31), MEL-TBI (14), BU-CY (25), CBV (11); Control
group: CY-TBI (31), MEL-TBI (16), BU-CY (19), CBV (14)• GVHD prophylaxis (intervention group : control group): methotrexate and cyclosporin for all partici-
pants who received allogeneic transplant
Interventions • Intervention group (N = 81): heparin 100 units/kg/day by continuous intravenous infusion from start
of conditioning till 30 days post-transplant or discharge from sterile unit, whichever occurred first• Control group (N = 80): no heparin infusion
Outcomes • Incidence of hepatic VOD• Overall survival• Mortality attributable to hepatic VOD• Frequency of adverse event (bleeding)
Notes • Duration of follow-up: 100 days post-transplant• Loss to follow-up (intervention group : control group): 0 : 0• The mean interval between diagnosis and BMT appeared to be shorter in the intervention group (12.8
months) compared to the control group (16.1 months)• Funding source: information not available• Declarations of interest: information not available
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomisation sequence prepared by biostatistics de-
partment
Allocation concealment
(selection bias)
Low risk Randomisation sequence unknown to the physicians participating in the trial,
treatment allocation assigned via telephone
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Neither participants nor personnel were blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Physicians who assessed for presence of clinical hepatic VOD were not blinded
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Follow-up was complete for all participants
Selective reporting (re-
porting bias)
Unclear risk Protocol was not available. It was unclear whether all pre-specified outcomes
were reported
Attal 1992  (Continued)
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Other bias High risk Diagnostic criteria or diagnostic evaluation for hepatic VOD was not uniform.
The interval between diagnosis and BMT appeared to be shorter in the inter-
vention group compared to the control group. Hence the 2 groups might not
be comparable at baseline
Attal 1992  (Continued)
 
 
Methods • Study design: parallel-group randomised controlled trial• Stratification factor: none• Settings: inpatients• Study dates: not reported• Location: UK
Participants • Inclusion criteria: people undergoing stem cell transplant• Exclusion criteria: information not available• Number of participants (intervention group : control group): 18 : 16• Number of men (intervention group : control group): 11 : 9• Age of participants (intervention group : control group): median (range) in years: 41 (19 - 62) : 32 (16
- 55)• Underlying diseases: Intervention group: AML (2), ALL (1), CML (2), myeloma (2), non-Hodgkin lym-
phoma (6), Hodgkin lymphoma (5); Control group: AML (3), ALL (0), CML (2), myeloma (1), non-Hodgkin
lymphoma (7), Hodgkin lymphoma (3)• Previous treatments (intervention group : control group): information not available.• Pre-existing liver dysfunction (intervention group : control group): information not available• Previous history of hepatic VOD (intervention group : control group): information not available• Performance status before transplant (intervention group : control group): information not available• Type of transplant: Intervention group: allogeneic (3), autologous (15); Control group: allogeneic (4),
autologous (12)• Donor (intervention group : control group): allogeneic (3), autologous (15); Control group: allogeneic
(4), autologous (12)• HLA disparity (intervention group : control group): information not available• Stem cell source: Intervention group: bone marrow (7), peripheral blood stem cell (11); Control group:
bone marrow (8), peripheral blood stem cell (8)• Stem cell manipulation (intervention group : control group): information not available• Conditioning regimen: Intervention group: BEAM (10), CY-TBI (4), BU-CY (4); Control group: BEAM (9),
CY-TBI (5), BU-CY (2)• GVHD prophylaxis (intervention group : control group): information not available
Interventions • Intervention group (N = 18): glycl-L-glutamine 50 g intravenous infusion daily from the start of condi-
tioning till discharge from the transplant unit• Control group (N = 16): placebo (isonitrogenous mixture of non-essential amino acids) 50 g intra-
venous infusion daily from the start of conditioning till discharge from the BMT unit
Outcomes • Incidence of hepatic VOD• All-cause mortality• Mortality attributable to hepatic VOD• Frequency of adverse events
Notes • Duration of follow-up: till discharge from BMT unit• Loss to follow-up (intervention group : control group): 0 : 0• Warfarin was used in 9 participants in the intervention group but only 2 participants in the control
group. 1 participant in the treatment group withdrew from the trial because of symptom of abdominal
Brown 1998 
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fullness. 3 other participants in the treatment group withdrew without reason given. 1 participant in
the control group withdrew treatment because of problems with the supply of amino acid solution.
Another participant in the control group did not complete treatment because he died soon from sepsis
and graJ-versus-host disease• Funding source: information not available• Declarations of interest: information not available
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Random sequence generation was not described
Allocation concealment
(selection bias)
Unclear risk Allocation concealment was not described
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Both participants and study personnel were blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Blinding of outcome assessors was not described
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Withdrawal of treatment occurred in some participants but their outcomes
were reported
Selective reporting (re-
porting bias)
Unclear risk Protocol was not available. It was unclear whether all pre-specified outcomes
were reported
Other bias High risk Warfarin was used more often in the intervention group compared to the con-
trol group. The participants in the intervention group also appeared to be old-
er than those in the control group. Hence the 2 groups might not be compara-
ble at baseline. Withdrawal of treatment occurred in 22% of participants in the
intervention group and 25% of participants in the control group which might
cause bias
Brown 1998  (Continued)
 
 
Methods • Study design: parallel-group randomised controlled trial• Stratification factor: stratified by centre and diagnosis of osteopetrosis• Settings: inpatients• Study dates: 25 January 2006 to 29 January 2009• Location: 28 centres in Europe
Participants • Inclusion criteria: age below 18 years, undergoing myeloablative conditioning for allogeneic or autol-
ogous stem cell transplant, and had one or more risk factors for hepatic VOD• Exclusion criteria: pregnant women, or people who were transplanted but did not fulfil inclusion cri-
teria• Number of participants (intervention group : control group): 181 : 179• Number of men (intervention group : control group): 110 : 101 (gender in 1 participant in intervention
group and 3 participants in control group unknown)
Corbacioglu 2012 
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• Age of participants (intervention group : control group): median (range) in years: 5.1 (0 - 18) : 4.6 (0 -
18) (age in 1 participant in intervention group and 3 participants in control group unknown)• Underlying diseases: intervention group: ALL (26), AML (31), MDS (20), other leukaemia (8), neuroblas-
toma (34), soJ tissue sarcoma (9), familial haemophagocytic lymphohistiocytosis (10), osteopetrosis
(7), adrenoleukodystrophy (1), others (34), unknown (1); control group: ALL (22), AML (42), MDS (11),
other leukaemia (5), neuroblastoma (33), soJ tissue sarcoma (8), familial haemophagocytic lympho-
histiocytosis (15), osteopetrosis (6), adrenoleukodystrophy (1), others (33), unknown (3)• Previous treatments: intervention group: stem cell transplant (25), abdominal irradiation (9), gem-
tuzumab (11), unknown (1); control group: stem cell transplant (23), abdominal irradiation (8), gem-
tuzumab (5), unknown (3)• Pre-existing liver dysfunction (intervention group : control group): 41 : 54 (unknown in 1 participant
in intervention group and 3 participants in control group)• Previous history of hepatic VOD (intervention group : control group): information not available• Performance status before transplant (intervention group : control group): information not available• Type of transplant: intervention group: allogeneic (122), autologous (53), no transplant (2), unknown
(4); control group: allogeneic (117), autologous (55), no transplant (1), unknown (6)• Donor: intervention group: matched related (35), matched unrelated (55), mismatched related (14),
mismatched unrelated (18), autologous (53), no transplant (2), unknown (4); control group: matched
related (25), matched unrelated (61), mismatched related (10), mismatched unrelated (21), autolo-
gous (55), no transplant (1), unknown (6)• HLA disparity: intervention group: HLA-matched (90), HLA-mismatched (32), autologous (53), no
transplant (2), unknown (4); control group: HLA-matched (86), HLA-mismatched (31), autologous (55),
no transplant (1), unknown (6)• Stem cell source: intervention group: bone marrow (79), peripheral blood stem cell (80), cord blood
(16), no transplant (2), unknown (4); control group: bone marrow (81), peripheral blood stem cell (81),
cord blood (10), no transplant (1), unknown (6).• Stem cell manipulation (intervention group : control group): T-cell depletion: 6 : 4 (unknown in 1 par-
ticipant in intervention group and 3 participants in control group).• Conditioning regimen: intervention group: intravenous busulfan (80), oral busulfan (46), melphalan
(126), cyclophosphamide (84), etoposide (22), fludarabine (34), treosulfan (13), TBI containing regi-
men (17), others (34), no transplant (2), unknown (4); control group: intravenous busulfan (81), oral
busulfan (44), melphalan (114), cyclophosphamide (80), etoposide (25), fludarabine (40), treosulfan
(13), TBI containing regimen (18), others (31), no transplant (1), unknown (6)• GVHD prophylaxis: intervention group: cyclosporin (100), methotrexate (56), ATG (horse) (2), ATG (rab-
bit) (65), alemtuzumab (9), muromonab-CD3 (11), others (31), no GVHD prophylaxis (53), no transplant
(2), unknown (4); control group: cyclosporin (104), methotrexate (65), ATG (horse) (2), ATG (rabbit) (80),
alemtuzumab (5), muromonab-CD3 (7), others (28), no GVHD prophylaxis (55), no transplant (1), un-
known (6)
Interventions • Intervention group (N = 181): defibrotide 6.25 mg/kg/dose every 6 hours intravenously over 2 hours
from the day of conditioning till day 30• Control group (N = 179): no treatment
Outcomes • Incidence of hepatic VOD• Overall survival• All-cause mortality at 100 days post-transplant• Mortality attributable to hepatic VOD• Frequency of adverse events
Notes • Duration of follow-up: 180 days• Loss to follow-up (intervention group : control group): 10 (1 did not provide consent, 2 had adverse
events, 1 transferred to another hospital, 6 unknown) : 10 (3 did not provide consent, 3 withdrew con-
sent, 2 had adverse event, 1 had relapse, 1 transferred to another hospital). Data were available for
338 participants (93.9%) at 30 days, 269 participants (74.7%) at 100 days, and 173 participants (48.1%)
at 180 days• Funding source: Gentium SpA and the European Blood and Marrow Transplantation (EBMT) Group
Corbacioglu 2012  (Continued)
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomisation sequence
Allocation concealment
(selection bias)
Low risk A data manager centrally assigned eligible participants on the basis of a com-
puter-generated randomisation sequence
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Neither participants nor study personnel were blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Blinding of outcome assessors was not described
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Data were available for only 48.1% of participants by the end of follow-up
Selective reporting (re-
porting bias)
Low risk All outcomes in the protocol were reported
Other bias Low risk No other bias is evident
Corbacioglu 2012  (Continued)
 
 
Methods • Study design: parallel-group randomised controlled trial• Stratification factor: none• Settings: inpatients• Study dates: not reported• Location: Belgium
Participants • Inclusion criteria: people undergoing stem cell transplant• Exclusion criteria: information not available• Number of participants: PGE1 group (47); heparin group (47); enoxaparin group (46)• Number of men: information not available• Age of participants: information not available• Underlying diseases: information not available• Previous treatments: information not available
Demuynck 1995 
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• Pre-existing liver dysfunction: information not available• Previous history of hepatic VOD: information not available• Performance status before transplant: information not available• Type of transplant: PGE1 group: allogeneic (14), autologous (33); heparin group: allogeneic (14), au-
tologous (33); enoxaparin group: allogeneic (15), autologous (31)• Donor: PGE1 group: allogeneic (14), autologous (33); heparin group: allogeneic (14), autologous (33);
enoxaparin group: allogeneic (15), autologous (31)• HLA disparity: information not available• Stem cell source: information not available• Stem cell manipulation: information not available• Conditioning regimen: information not available• GVHD prophylaxis (intervention group : control group): information not available
Interventions • PGE1 group (N = 47): prostaglandin E1 500 microgram/kg/day intravenous infusion• Heparin group (N = 47): heparin 100 units/kg/day intravenous infusion• Enoxaparin group (N = 46): enoxaparin 20 mg/day subcutaneous injection
Outcomes • Incidence of hepatic VOD• Mortality attributable to hepatic VOD• Frequency of adverse events
Notes • Duration of follow-up: information not available.• Loss to follow-up: information not available.• Funding source: information not available.• Declarations of interest: information not available.• Information based on abstract only
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Random sequence generation was not described
Allocation concealment
(selection bias)
Unclear risk Allocation concealment was not described
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Neither participants nor study personnel were blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Blinding of outcome assessors was not described
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Dropout was not described
Selective reporting (re-
porting bias)
Unclear risk Protocol was not available. It was unclear whether all pre-specified outcomes
were reported
Demuynck 1995  (Continued)
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Other bias Unclear risk We were not certain whether important baseline characteristics of the partici-
pants in different treatment groups were comparable or not. We were also not
certain whether different treatment groups received same co-interventions
Demuynck 1995  (Continued)
 
 
Methods • Study design: parallel-group randomised controlled trial• Stratification factor: none• Settings: inpatients• Study dates: 24 February 1992 to 4 August 1994• Location: USA
Participants • Inclusion criteria: allogeneic bone marrow transplant from a related donor using busulfan and cy-
clophosphamide as conditioning• Exclusion criteria: impaired creatinine clearance (< 50 ml/min), pregnancy, lactation, allergy to bile
acids, failure to give informed consent• Number of participants (intervention group : control group): 35 : 32• Number of men (intervention group : control group): 22 :20• Age of participants (intervention group : control group): mean (range) in years: 38 (22 - 56) : 37 (21 - 56)• Underlying diseases: Intervention group: AML (5), ALL (3), CML (20), myeloma (3), myelodysplastic syn-
drome (2), myelofibrosis (0), Castleman disease (1), paroxysmal nocturnal haemoglobinuria (1); Con-
trol group: AML (9), ALL (3), CML (12), myeloma (3), myelodysplastic syndrome (1), myelofibrosis (2),
Castleman disease (0), paroxysmal nocturnal haemoglobinuria (2)• Previous treatments (intervention group : control group): more than 1 cytotoxic regimen: 10 : 10• Pre-existing liver dysfunction (intervention group : control group): elevated AST: 3 : 3• Previous history of hepatic VOD (intervention group : control group): information not available• Performance status before transplant (intervention group : control group): mean Karnofsky perfor-
mance score (range): 85 (70 - 100) : 83 (70 - 100)• Type of transplant: all participants received allogeneic bone marrow transplant from a related donor• Donor: all participants received allogeneic transplant from a related donor• HLA disparity (intervention group : control group): information not available• Stem cell source: all participants received bone marrow• Stem cell manipulation (intervention group : control group): information not available• Conditioning regimen: all participants received busulfan and cyclophosphamide• GVHD prophylaxis: all participants received methotrexate and cyclosporin
Interventions • Intervention group (N = 35): ursodiol 300 mg twice daily orally (body weight < 90 kg), or 300 mg/600
mg twice daily (body weight > 90 kg), from before start of conditioning till 80 days post-transplant• Control group (N = 32): placebo capsules with same appearance twice daily orally from before start of
conditioning till 80 days post-transplant
Outcomes • Incidence of hepatic VOD• Overall survival• All-cause mortality at 100 days post-transplant• Mortality attributable to hepatic VOD• Frequency of adverse events
Notes • Duration of follow-up: 1 year post-transplant• Loss to follow-up (intervention group : control group): 1 (reason not provided) : 0• Donor-recipient blood group mismatch was less frequent in the intervention group (23%) compared
to the control group (50%). Methexate was truncated less frequently in the intervention group (3%)
compared to the control group (19%)
Essell 1998 
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• Funding source: Summit Pharmaceuticals supplied the study drug and placebo• Declarations of interest: No financial assistance was provided
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Cards labelled "ursodiol" and "placebo" were placed in sealed opaque en-
velops and then randomised and given consecutive numbers. Randomization
was done by pharmacist not involved in clinical care of patients.
Allocation concealment
(selection bias)
Low risk Allocation cards were put into sealed, opaque, numbered envelops
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Both participants and personnel were blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcome assessors were blinded
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk There was only 1 dropout (3%) in the intervention group and unlikely to have
significant influence on the overall outcome
Selective reporting (re-
porting bias)
Unclear risk Protocol was not available. It was unclear whether all pre-specified outcomes
were reported
Other bias High risk Donor-recipient blood group mismatch was less frequent in the intervention
group compared to the control group. Diagnosis of CML was more frequent
in the intervention group compared to the control group. Hence the 2 groups
might not be comparable at baseline. Methexate was truncated less frequent-
ly in the intervention group (3%) compared to the control group (19%). The dif-
ference in this co-intervention might cause bias
Essell 1998  (Continued)
 
 
Methods • Study design: parallel-group randomised controlled trial• Stratification factor: none• Settings: inpatients• Study dates: not reported• Location: Korea
Participants • Inclusion criteria: people undergoing stem cell transplant• Exclusion criteria: information not available• Number of participants (intervention group : control group): 14 : 16• Number of men (intervention group : control group): information not available• Age of participants (intervention group : control group): information not available• Underlying diseases: both groups: AML (9), ALL (4), acute biphenotypic leukaemia (2), CML (3), small
lymphocytic leukaemia (1), myeloma (2), myelodysplastic syndrome (1), non-Hodgkin lymphoma (6),
Hodgkin lymphoma (1), aplastic anaemia (1)• Previous treatments (intervention group : control group): information not available.• Pre-existing liver dysfunction (intervention group : control group): information not available
Jung 2005 
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• Previous history of hepatic VOD (intervention group : control group): information not available• Performance status before transplant (intervention group : control group): information not available• Type of transplant: both groups: allogeneic (17), autologous (13)• Donor: both groups: sibling (13), unrelated (4), autologous (13)• HLA disparity (intervention group : control group): information not available• Stem cell source: both groups: bone marrow or peripheral blood stem cells (29), cord blood (1)• Stem cell manipulation (intervention group : control group): information not available• Conditioning regimen (intervention group : control group): information not available• GVHD prophylaxis (intervention group : control group): information not available
Interventions • Intervention group (N = 14): antithrombin III 1000 units twice daily intravenously from day 1 till day
14 post-transplant and heparin 5 units/kg/hour intravenous infusion from day 1 till day 21 post-trans-
plant or discharge after transplant• Control group (N = 16): heparin 5 units/kg/hour intravenous infusion from day 1 till day 21 post-trans-
plant or discharge after transplant
Outcomes • Incidence of hepatic VOD• Mortality attributable to hepatic VOD• Frequency of adverse event (bleeding)
Notes • Duration of follow-up: information not available• Loss to follow-up (intervention group : control group): information not available• Funding source: information not available• Declarations of interest: information not available• Information based on abstract only
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Random sequence generation was not described
Allocation concealment
(selection bias)
Unclear risk Allocation concealment was not described
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Neither participants nor study personnel were blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Blinding of outcome assessors was not described
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Dropout was not described.
Selective reporting (re-
porting bias)
Unclear risk Protocol was not available. It was unclear whether all pre-specified outcomes
were reported.
Other bias Unclear risk We were not certain whether important baseline characteristics of the partici-
pants in different treatment groups were comparable or not. We were also not
certain whether different treatment groups received same co-interventions.
Jung 2005  (Continued)
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Methods • Study design: parallel-group randomised controlled trial• Stratification factor: none• Settings: inpatients• Study dates: not reported• Location: Singapore
Participants • Inclusion criteria: people with haematological malignancies undergoing bone marrow transplant• Exclusion criteria: information not available• Number of participants (intervention group : control group): 23 : 22• Number of men (intervention group : control group): information not available• Age of participants (intervention group : control group): information not available• Underlying diseases: all participants had haematological malignancies• Previous treatments (intervention group : control group): information not available• Pre-existing liver dysfunction (intervention group : control group): information not available• Previous history of hepatic VOD (intervention group : control group): information not available• Performance status before transplant (intervention group : control group): information not available• Type of transplant (intervention group : control group): information not available• Donor (intervention group : control group): information not available• HLA disparity (intervention group : control group): information not available• Stem cell source: all participants received bone marrow• Stem cell manipulation (intervention group : control group): information not available• Conditioning regimen (intervention group : control group): information not available• GVHD prophylaxis (intervention group : control group): information not available
Interventions • Intervention group (N = 23): nadroparin calcium• Control group (N = 22): no nadroparin calcium
Outcomes • Incidence of hepatic VOD• Frequency of adverse event (bleeding)
Notes • Duration of follow-up: information not available• Loss to follow-up (intervention group : control group): information not available• Funding source: information not available• Declarations of interest: information not available• Information based on abstract only
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Random sequence generation was not described
Allocation concealment
(selection bias)
Unclear risk Allocation concealment was not described
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Neither participants nor study personnel were blinded
Lee 1996 
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Blinding of outcome assessors was not described
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Dropout was not described
Selective reporting (re-
porting bias)
Unclear risk Protocol was not available. It was unclear whether all pre-specified outcomes
were reported
Other bias Unclear risk We were not certain whether important baseline characteristics of the partici-
pants in different treatment groups were comparable or not. We were also not
certain whether different treatment groups received same co-interventions
Lee 1996  (Continued)
 
 
Methods • Study design: parallel-group randomised controlled trial• Stratification factor: none• Settings: inpatients• Study dates: October 1984 to March 1989• Location: France
Participants • Inclusion criteria: people with haematological malignancies and solid tumours undergoing autolo-
gous bone marrow transplant• Exclusion criteria: people with an increased risk to develop hepatic VOD• Number of participants (intervention group : control group): 52 : 46• Number of men (intervention group : control group): information not available• Age of participants (intervention group : control group): information not available• Underlying diseases: haematological malignancies or solid tumours• Previous treatments (intervention group : control group): information not available• Pre-existing liver dysfunction (intervention group : control group): information not available• Previous history of hepatic VOD (intervention group : control group): information not available• Performance status before transplant (intervention group : control group): information not available• Type of transplant: both groups: autologous bone marrow transplant• Donor: both groups: autologous• HLA disparity: both groups: autologous• Stem cell source: all participants received bone marrow• Stem cell manipulation (intervention group : control group): information not available• Conditioning regimen (intervention group : control group): information not available• GVHD prophylaxis: not applicable
Interventions • Intervention group (N = 52): heparin 1 mg/kg/day intravenous infusion from day 0 to haematological
reconstitution and discharge• Control group (N = 46): no heparin
Outcomes • Incidence of hepatic VOD
Notes • Duration of follow-up: information not available• Loss to follow-up (intervention group : control group): information not available• Funding source: Consejeria de Educacion of the Canary Islands Government, Spain• Declarations of interest: information not available
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Random sequence generation was not described
Allocation concealment
(selection bias)
Unclear risk Allocation concealment was not described
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Neither participants nor study personnel were blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Blinding of outcome assessors was not described
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Dropout was not described
Selective reporting (re-
porting bias)
Unclear risk Protocol was not available. It was unclear whether all pre-specified outcomes
were reported
Other bias Unclear risk We were not certain whether important baseline characteristics of the partici-
pants in different treatment groups were comparable or not. We were also not
certain whether different treatment groups received same co-interventions
Marsa-Vila 1991  (Continued)
 
 
Methods • Study design: parallel-group randomised controlled trial• Stratification factor: stratified by age to 2 groups: ≤ 18 years and > 18 years• Settings: inpatients• Study dates: April 2001 to March 2003• Location: Japan
Participants • Inclusion criteria: allogeneic transplant and 1 of the following: 1. intensified conditioning regimen, 2.
second transplant, 3. liver dysfunction, 4. intensified chemotherapy until just before transplant• Exclusion criteria: information not available• Number of participants (intervention group : control group): 24 : 23• Number of men (intervention group : control group): 15 : 16 (gender in 1 participant in intervention
group and 3 participants in control group unknown)• Age of participants (intervention group : control group): range in years: 1 - 54 : 1 - 64 (age in 1 participant
in intervention group and 3 participants in control group unknown)• Underlying diseases: intervention group: ALL (4), AML (8), MDS (4), CML (3), NHL (2), aplastic anaemia
(1), Wiskott Aldrich syndrome (1), unknown (1); control group: ALL (8), AML (5), MDS (2), CML (1), NK-
leukaemia (1), NHL (1); Hodgkin lymphoma (1), chronic active EBV infection (1), unknown (3)• Previous treatments (intervention group : control group): information not available• Pre-existing liver dysfunction (intervention group : control group): information not available• Previous history of hepatic VOD (intervention group : control group): information not available• Performance status before transplant (intervention group : control group): information not available• Type of transplant: both groups: allogeneic
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• Donor: intervention group: related (8), unrelated (15), unknown (1); control group: related (6), unre-
lated (14), unknown (3)• HLA disparity (intervention group : control group): information not available• Stem cell source: intervention group: bone marrow (7), peripheral blood stem cell (5), cord blood (11),
unknown (1); control group: bone marrow (9), peripheral blood stem cell (5), cord blood (6), unknown
(3)• Stem cell manipulation (intervention group : control group): information not available• Conditioning regimen: intervention group: myeloablative (20), non-myeloablative (3), unknown (1);
control group: myeloablative (17), non-myeloablative (3), unknown (3)• GVHD prophylaxis: intervention group: cyclosporin/methotrexate (5), tacrolimus/methotrexate (7),
tacrolimus/methotrexate/prednisolone (1), cyclosporin (6), tacrolimus (4), unknown (1); control
group: cyclosporin/methotrexate (11), tacrolimus/methotrexate (2), cyclosporin (1), tacrolimus (5),
none (1), unknown (3)
Interventions • Intervention group (N = 24): fresh frozen plasma intravenous infusion twice weekly from conditioning
till day 28. Volume: < 10 kg: 80 ml; 10 - 20 kg: 160 ml; 20 - 30 kg: 240 ml; 30 - 40 kg: 320 ml; > 40 kg: 400 ml• Control group (N = 23): no fresh frozen plasma
Outcomes • Incidence of hepatic VOD
Notes • Duration of follow-up: 28 days• Loss to follow-up (intervention group : control group): 1 (could not undergo transplant because of
poor physical condition): 3 (could not undergo transplant because of poor physical condition)• Funding source: Ministry of Education, Culture, Sports, Science and Technology; and Ministry of
Health, Labour and Welfare of Japan• Declarations of interest: information not available
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Random sequence generation was not described
Allocation concealment
(selection bias)
Unclear risk Allocation concealment was not described
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Neither participants nor study personnel were blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Blinding of outcome assessors was not described
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Dropouts occurred in 4% of intervention group and 13% of control group and
might cause bias
Selective reporting (re-
porting bias)
Unclear risk Protocol was not available. It was unclear whether all pre-specified outcomes
were reported
Other bias High risk Some baseline characteristics of both groups were quite different and there-
fore the 2 groups might not be comparable. These included a lower propor-
tion of ALL and higher proportion of cord blood transplant in the intervention
group compared with the control group. There were more participants receiv-
Matsumoto 2007  (Continued)
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ing cyclosporin and fewer participants receiving combined cyclosporin and
methotrexate as GVHD prophylaxis in the intervention group compared with
the control group
Matsumoto 2007  (Continued)
 
 
Methods • Study design: parallel-group randomised controlled trial• Stratification factor: none• Settings: inpatients• Study dates: June 1996 to February 1998• Location: Japan
Participants • Inclusion criteria: people undergoing stem cell transplant• Exclusion criteria: information not available• Number of participants (intervention group : control group): 71 : 65• Number of men (intervention group : control group): 40 : 30 (gender in 4 participants in intervention
group unknown)• Age of participants (intervention group : control group): mean in years: 34.5 : 35.7 (age in 4 participants
in intervention group unknown)• Underlying diseases: intervention group: ALL (15), acute non-lymphocytic leukaemia (23), MDS (4),
CML (15), lymphoma (3), aplastic anaemia (3), others (4), unknown (4); control group: ALL (12), acute
non-lymphocytic leukaemia (19), MDS (4), CML (15), lymphoma (8), aplastic anaemia (5), others (2)• Previous treatments (intervention group : control group): information not available• Pre-existing liver dysfunction (intervention group : control group): information not available• Previous history of hepatic VOD (intervention group : control group): information not available• Performance status before transplant (intervention group : control group): information not available• Type of transplant: intervention group: allogeneic (61), autologous (6), unknown (4); control group:
allogeneic (56), autologous (9)• Donor: intervention group: related (39), unrelated (22), autologous (6), unknown (4); control group:
related (31), unrelated (25), autologous (9)• HLA disparity: intervention group: genotypically identical (29), phenotypically identical (8), mis-
matched (2), unknown (4); control group: genotypically identical (27), phenotypically identical (4),
mismatched (0)• Stem cell source (intervention group : control group): information not available• Stem cell manipulation (intervention group : control group): information not available• Conditioning regimen: intervention group: chemotherapy only (23), chemotherapy and TBI (34),
chemotherapy and TLI (10), unknown (4); control group: chemotherapy only (18), chemotherapy and
TBI (37), chemotherapy and TLI (10)• GVHD prophylaxis: intervention group: cyclosporin/methotrexate (60), tacrolimus/methotrexate (0),
cyclosporin (1), unknown (4); control group: cyclosporin/methotrexate (53), tacrolimus/methotrexate
(1), cyclosporin (2)
Interventions • Intervention group (N = 71): ursodeoxycholic acid 600 mg/day orally from day -21 till day 80• Control group (N = 65): no ursodeoxycholic acid
Outcomes • Incidence of hepatic VOD• All-cause mortality• Mortality attributable to hepatic VOD• Frequency of adverse events
Notes • Duration of follow-up: 24 weeks• Loss to follow-up (intervention group : control group): 4 (1 died due to regimen-related toxicity, 1 did
not undergo transplant, 2 could not retrieve data sheets) : 0
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• Funding source: information not available• Declarations of interest: information not available
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Random sequence generation was not described
Allocation concealment
(selection bias)
Unclear risk Allocation concealment was not described
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Neither participants nor study personnel were blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Blinding of outcome assessors was not described
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Dropouts occurred in 6% of intervention group and none of control group and
might cause bias
Selective reporting (re-
porting bias)
Unclear risk Protocol was not available. It was unclear whether all pre-specified outcomes
were reported
Other bias High risk Some baseline characteristics of both groups were quite different and there-
fore the 2 groups might not be comparable. These included a higher propor-
tion of men and lower proportion of lymphoma in the intervention group com-
pared with the control group
Ohashi 2000  (Continued)
 
 
Methods • Study design: parallel-group randomised controlled trial• Stratification factor: stratified by type of transplant to 2 groups: allogeneic and autologous• Settings: inpatients• Study dates: August 1992 to December 1993• Location: Israel
Participants • Inclusion criteria: people above 15 years with malignant disease undergoing stem cell transplant• Exclusion criteria: pre-transplant platelet < 20x109/L, history of major thrombotic or bleeding event,
allergy to heparin• Number of participants (intervention group : control group): 28 : 33• Number of men (intervention group : control group): 14 : 11• Age of participants (intervention group : control group): mean (SD) in years: 40 (9.9) : 34 (10.2)• Underlying diseases: intervention group: ALL (2), AML (3), MDS (2), CML (3), CLL (1), NHL (9), Hodgkin
lymphoma (2), multiple myeloma (1), solid tumour (4); control group: ALL (3), AML (6), MDS (0), CML
(9), CLL (0), NHL (7), Hodgkin lymphoma (2), multiple myeloma (1), solid tumour (6)• Previous treatments (intervention group : control group): information not available• Pre-existing liver dysfunction (intervention group : control group): elevated bilirubin: 1 : 2• Previous history of hepatic VOD (intervention group : control group): information not available
Or 1996 
Interventions for prophylaxis of hepatic veno-occlusive disease in people undergoing haematopoietic stem cell transplantation (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
54
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
• Performance status before transplant (intervention group : control group): information not available• Type of transplant: intervention group: allogeneic (8), autologous (20); control group: allogeneic (16),
autologous (17)• Donor: (intervention group : control group): information not available• HLA disparity: (intervention group : control group): information not available• Stem cell source (intervention group : control group): information not available• Stem cell manipulation (intervention group : control group): information not available• Conditioning regimen: intervention group: TECAM (12), CTEM (4), ECYM and TBI (4), ECYM and TBI and
TLI (5), Bu-T-CY (2), mitoxantrone and TBI (1); control group: TECAM (7), CTEM (6), ECYM and TBI (9),
ECYM and TBI and TLI (6), Bu-T-CY (4), mitoxantrone and TBI (1)• GVHD prophylaxis (intervention group : control group): information not available
Interventions • Intervention group (N = 28): enoxaparin 40 mg daily by subcutaneous injection to abdominal wall from
day -1 till discharge or day 40• Control group (N = 33): placebo (normal saline)
Outcomes • Frequencies of hyperbilirubinaemia, hepatic enlargement, right upper quadrant abdominal pain, as-
cites, and weight gain• Frequency of adverse event (bleeding)
Notes • Duration of follow-up: information not available• Loss to follow-up (intervention group : control group): 0 : 0• Funding source: Robert A. Rosenblum Research Fund• Declarations of interest: information not available
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Random sequence generation was not described
Allocation concealment
(selection bias)
Unclear risk Allocation concealment was not described
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Both participants and study personnel were blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcome assessors were blinded
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk There was no dropout
Selective reporting (re-
porting bias)
Unclear risk Protocol was not available. It was unclear whether all pre-specified outcomes
were reported
Other bias High risk Some baseline characteristics of both groups were quite different and there-
fore the 2 groups might not be comparable. These included a higher propor-
tion of men and lower proportion of chronic myeloid leukaemia and allogene-
ic stem cell transplant in the intervention group compared with the control
group. The participants in the intervention group also had a higher mean age
Or 1996  (Continued)
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Methods • Study design: parallel-group randomised controlled trial• Stratification factor: none• Settings: inpatients• Study dates: February 1996 to January 2001• Location: Korea
Participants • Inclusion criteria: adults undergoing stem cell transplant• Exclusion criteria: life-threatening gastrointestinal or central nervous system bleeding within 2
months prior to stem cell transplant, history of allergic reaction to either heparin or ursodiol• Number of participants (intervention group : control group): 82 : 83• Number of men (intervention group : control group): 41 : 40• Age of participants (intervention group : control group): median in years: 39 : 38• Underlying diseases: intervention group: acute leukaemia (23), CML (9), lymphoma (14), solid tumour
(15), aplastic anaemia (9), others (12); control group: acute leukaemia (32), CML (12), lymphoma (6),
solid tumour (18), aplastic anaemia (6), others (9)• Previous treatments (intervention group : control group): information not available• Pre-existing liver dysfunction (intervention group : control group): information not available• Previous history of hepatic VOD (intervention group : control group): information not available• Performance status before transplant (intervention group : control group): information not available• Type of transplant: intervention group: allogeneic (38), autologous (44); control group: allogeneic (43),
autologous (40)• Donor: (intervention group : control group): information not available• HLA disparity: (intervention group : control group): information not available• Stem cell source (intervention group : control group): information not available• Stem cell manipulation (intervention group : control group): information not available• Conditioning regimen: intervention group: busulfan and cyclophosphamide (13), TBI containing reg-
imen (27), others (42); control group: busulfan and cyclophosphamide (16), TBI containing regimen
(31), others (36)• GVHD prophylaxis (intervention group : control group): information not available
Interventions • Intervention group (N = 82): heparin 5 units/kg/hour by continuous intravenous infusion and ursodiol
300 mg every 12 hours orally from 12 - 24 hours before conditioning till discharge or day 30• Control group (N = 83): heparin alone
Outcomes • Incidence of hepatic VOD• Overall survival• All-cause mortality at 100 days post-transplant• Mortality attributable to hepatic VOD• Frequency of adverse event (bleeding)
Notes • Duration of follow-up: information not available• Loss to follow-up (intervention group : control group): 0 : 0• Funding source: information not available• Declarations of interest: information not available
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Random sequence generation was not described
Park 2002 
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Allocation concealment
(selection bias)
Unclear risk Allocation concealment was not described
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Neither participants nor study personnel were blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Blinding of outcome assessors was not described
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk There was no dropout
Selective reporting (re-
porting bias)
Unclear risk Protocol was not available. It was unclear whether all pre-specified outcomes
were reported
Other bias High risk Some baseline characteristics of both groups were quite different and there-
fore the 2 groups might not be comparable. These included a higher propor-
tion of lymphoma and lower proportion of acute leukaemia in the intervention
group compared with the control group
Park 2002  (Continued)
 
 
Methods • Study design: parallel-group randomised controlled trial• Stratification factor: stratified by risk of disease (low risk or high risk), type of donor (HLA-identical
sibling, other related donor, or unrelated donor), conditioning (with or without TBI), and centre (3
centres)• Settings: inpatients• Study dates: January 1996 to November 1998• Location: Finland and Sweden
Participants • Inclusion criteria: people undergoing allogeneic stem cell transplant• Exclusion criteria: information not available• Number of participants (intervention group : control group): 124 : 120• Number of men (intervention group : control group): 61 : 61 (gender in 1 participant in each group
unknown)• Age of participants (intervention group : control group): median (range) in years: 38 (5 - 59) : 40 (1 - 58)
(age in 1 participant in each group unknown)• Underlying diseases: intervention group: ALL (26), AML (38), CML (31), CLL (2), MDS (11), NK cell
leukaemia (0), multiple myeloma (2), myelofibrosis (2), essential thrombocythaemia (0), hypere-
osinophilic syndrome (1), NHL (2), aplastic anaemia (3), Fanconi anaemia (1), amegakaryocytic throm-
bocytopenia (1), chronic granulomatous disease (1), familial haemophagocytic lymphohistiocytosis
(1), aspartylglucosaminuria (1), unknown (1); control group: ALL (24), AML (34), CML (37), CLL (2), MDS
(12), NK cell leukaemia (1), multiple myeloma (3), myelofibrosis (1), essential thrombocythaemia (1),
hypereosinophilic syndrome (0), NHL (2), aplastic anaemia (0), Fanconi anaemia (0), amegakaryocytic
thrombocytopenia (0), chronic granulomatous disease (1), familial haemophagocytic lymphohistio-
cytosis (1), aspartylglucosaminuria (0), unknown (1)• Previous treatments (intervention group : control group): information not available• Pre-existing liver dysfunction (intervention group : control group): information not available• Previous history of hepatic VOD (intervention group : control group): information not available• Performance status before transplant (intervention group : control group): information not available
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• Type of transplant: all participants received allogeneic transplant• Donor: intervention group: matched sibling (64), other family member (2), unrelated (57), no trans-
plant (1); control group: matched sibling (68), other family member (0), unrelated (51), no transplant
(1)• HLA disparity: (intervention group : control group): information not available• Stem cell source: intervention group: bone marrow (97), peripheral blood stem cell (26), no transplant
(1); control group: bone marrow (93), peripheral blood stem cell (26), no transplant (1)• Stem cell manipulation (intervention group : control group): information not available• Conditioning regimen: intervention group: cytostatic drugs only regimen (11), TBI containing regimen
(112), no transplant (1); control group: cytostatic drugs only regimen (12), TBI containing regimen
(107), no transplant (1)• GVHD prophylaxis: intervention group: cyclosporin/methotrexate (63), cyclosporin/methyl-
prednisolone (0), methotrexate/methylprednisolone (0), cyclosporin/methotrexate/methylpred-
nisolone (57), cyclosporin/methotrexate/T-cell depletion (3), no transplant (1); control group:
cyclosporin/methotrexate (60), cyclosporin/methylprednisolone (3), methotrexate/methylpred-
nisolone (1), cyclosporin/methotrexate/methylprednisolone (55), cyclosporin/methotrexate/T-cell
depletion (0), no transplant (1)
Interventions • Intervention group (N = 124): ursodeoxycholic acid 6 mg/kg/dose twice daily orally from the day of
conditioning till day 90• Control group (N = 120): placebo
Outcomes • Incidence of hepatic VOD• Overall survival• All-cause mortality at 100 days post-transplant• Mortality attributable to hepatic VOD• Frequency of adverse event (bleeding)
Notes • Duration of follow-up: information not available• Loss to follow-up (intervention group : control group): 1 (died before transplantation) : 1 (cancellation
of transplantation)• Funding source: information not available• Declarations of interest: information not available
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Random sequence generation was not described
Allocation concealment
(selection bias)
Unclear risk Allocation concealment was not described
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Niether participants nor study personnel were blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Blinding of outcome assessors was not described.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk There was only 1 dropout in each group and unlikely to have significant influ-
ence on the overall outcome
Ruutu 2002  (Continued)
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Selective reporting (re-
porting bias)
Unclear risk Protocol was not available. It was unclear whether all pre-specified outcomes
were reported
Other bias Low risk No other bias was identified
Ruutu 2002  (Continued)
 
 
Methods • Study design: parallel-group randomised controlled trial• Stratification factor: none• Settings: inpatients• Study dates: not reported• Location: Greece
Participants • Inclusion criteria: people who underwent haematopoietic stem cell transplant• Exclusion criteria: information not available• Number of participants (intervention group : control group): 172 : 164• Number of men (intervention group : control group): information not available• Age of participants (both groups): median (range) in years: 36 (5 - 68)• Underlying diseases (intervention group : control group): information not available• Previous treatments (intervention group : control group): information not available• Pre-existing liver dysfunction (intervention group : control group): information not available• Previous history of hepatic VOD (intervention group : control group): information not available• Performance status before transplant (intervention group : control group): information not available• Type of transplant (both groups): autologous (152), allogeneic (184)• Donor (both groups): autologous (152), matched sibling (117), unrelated donor (61), others (6)• HLA disparity (intervention group : control group): information not available• Stem cell source (intervention group : control group): information not available• Stem cell manipulation (intervention group : control group): information not available• Conditioning regimen (both groups): busulfan (125), others (211)• GVHD prophylaxis (intervention group : control group): information not available
Interventions • Intervention group (N = 172): fresh frozen plasma and heparin• Control group (N = 164): heparin alone
Outcomes • Incidence of hepatic VOD
Notes • Duration of follow-up: 100 days• Loss to follow-up (intervention group : control group): 0 : 0• Funding source: information not available• Declarations of interest: information not available• Information based on abstract only
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Random sequence generation was not described
Allocation concealment
(selection bias)
Unclear risk Allocation concealment was not described
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Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Neither participants nor study personnel were blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Blinding of outcome assessors was not described
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk There was no dropout
Selective reporting (re-
porting bias)
Unclear risk Protocol was not available. It was unclear whether all pre-specified outcomes
were reported
Other bias Unclear risk We were not certain whether important baseline characteristics of the partici-
pants in different treatment groups were comparable or not. We were also not
certain whether different treatment groups received same co-interventions
Yannaki 2012  (Continued)
ALL: acute lymphoblastic leukaemia; AML: acute myeloid leukaemia; AST: aspartate aminotransferase; ATG: anti-thymocyte globulin;
BEAM: carmustine, etoposide, cytarabine, melphalan; BMT: bone marrow transplantation; BU: busulfan; CBV: cyclophosphamide,
carmustine, etoposide; CLL: chronic lymphocytic leukaemia; CML: chronic myeloid leukaemia; CTEM: cyclophosphamide, thiotepa,
etoposide, melphalan; CY: cyclophosphamide; EBV: Ebstein-Barr virus; ECYM: etoposide, cyclophosphamide, melphalan; GVHD: graJ-
versus-host disease; HLA: human leukocyte antigen; MDS: myelodysplastic syndrome; MEL: melphalan; NHL: non-Hodgkin lymphoma;
NK: natural killer; PGE1: prostaglandin E1; SD: standard deviation; T: thiotepa; TBI: total body irradiation; TECAM: thiotepa, etoposide,
cyclophosphamide, cytarabine, melphalan; TLI: total lymphoid irradiation; VOD: veno-occlusive disease
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Carbacioglu 2004 Trial on treatment of hepatic veno-occlusive disease and not prophylaxis
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title Efficacy and safety study of defibrotide (DF) for the prophylaxis of veno-occlusive disease (VOD)
Methods Parallel-group randomised controlled trial
Participants Inclusion criteria:
1. 0 - 50 years old (at informed consent)
2. Primary disease is one of the following:
-malignant tumour not in remission
-malignant tumour in remission.
-osteopetrosis
-non-malignant disease other than osteopetrosis
3. People with 1 or more following risk factors of hepatic VOD who undergo allogeneic stem cell
transplantation with myeloablative conditioning regimen:
-Second myeloablative transplant
-Not in remission at transplant
-Performance status (ECOG) of 2 or more
JPRN-UMIN000013455 
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-Conditioning regimen including BU-MEL or BU-CY
-Liver dysfunction before stem cell transplant
-Positive for anti-HCV antibody
-Administration of gemtuzumab ozogamicin within 100 days before stem cell transplant
-Osteopetrosis
4. Witten informed consent to participate in the study from the participant or legally acceptable
representative before screening tests
Exclusion criteria:
1. Using medication that increases risk of haemorrhage
2. Acute bleeding that is not controlled
3. Unstable haemodynamic status that require more than 1 vasopressor or decreased mean atrial
pressure (MAP)
4. Complicated with viral fulminant hepatitis
5. Past history of organ transplant other than hematopoietic cell transplant
6. Complicated with grade IV GVHD
7. Women with pregnancy, breastfeeding, possible pregnancy. Men who will not consent to contra-
ception
8. Judged as inappropriate for participating in the study by the principal or other investigator for
other reasons
Interventions • Intervention group: intravenous infusion of defibrotide 6.25 mg/kg/dose over 2 hours every 6
hours, from 1 day before starting conditioning regimen until day 30 post-transplant (for a maxi-
mum of 100 days after transplantation)• Control group: standard treatment only
Outcomes Primary outcome:
Incidence of hepatic VOD until day 30 post-transplant
Principal or other investigator should evaluate the development of hepatic VOD according to the
revised Seattle criteria. Hepatic VOD is defined as those who meet at least 2 of the following criteria
by day 35 post stem cell transplant:
-Total Bilirubin ≥ 2 mg/dL
-Hepatomegaly
-Right hypochondriac pain
-Ascites
-Unexplained weight gain of more than 5% from baseline
Secondary outcomes:
1) Incidence of hepatic VOD at day 100 post-transplant
2) Incidence of hepatic VOD according to the Baltimore criteria at day 30 and day 100 post-trans-
plant
3) Severity of hepatic VOD in people who developed VOD
4) Incidence of total, grade II-IV, and III-IV acute GVHD at day 100 post-transplant
5) Survival at day 100 and day 180 post-transplant
6) Survival at day 100 and day 180 post-transplant in people who developed hepatic VOD
7) Incidence and severity of adverse events and drug-related adverse event
8) Date of engraftment
9) Remission status of the original disease at day 30, 100, and 180 after stem cell transplant in peo-
ple with malignancy
Starting date 7 March 2014
Contact information • Name: Miwa Izutsu• Address: 3-3-2Tsukiji, Chuo-ku, Tokyo, 140-0045, Japan• Telephone: 03-6228-4835• Email: chosei@fmu-df.jp
JPRN-UMIN000013455  (Continued)
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JPRN-UMIN000013455  (Continued)
 
 
Trial name or title A randomised control study on the effects of glutamine on the clinical outcome of bone marrow
transplant recipients with special reference to veno-occlusive disease and mucositis
Methods Parallel-group randomised controlled trial
Participants Inclusion Criteria:
Aged above 18 years
Allogeneic bone marrow transplant recipients using busulfan and cyclophosphamide as condition-
ing
Interventions • Intervention group: glutamine added to parenteral nutrition• Control group: standard parenteral nutrition
Outcomes Primary outcomes:
Mucositis at 1 month
Veno-occlusive disease at 1 month
Secondary outcomes:
Hospital stay (up to 2 months)
Use of antibiotics (up to 2 months)
Starting date July 2004
Contact information • Name: Dr YH Leung• Address: Department of Medicine/Division of Haematology, Queen Mary Hospital, Hong Kong• Telephone: (852) 2855 3347• Email: ayhleung@hku.hk
Notes  
NCT00563498 
BU: busulfan; CY: cyclophosphamide; ECOG: Eastern Cooperative Oncology Group; GVHD: graJ-versus-host disease; HCV: hepatitis C virus;
MEL: melphalan
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Ursodeoxycholic acid versus placebo or no treatment
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Incidence of hepatic VOD 4 612 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.40, 0.88]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
2 Overall survival 3 474 Hazard Ratio (95% CI) 0.83 [0.59, 1.18]
3 All-cause mortality at 100 days
post-transplant
4 612 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.50, 0.99]
4 Mortality attributable to hepat-
ic VOD
4 612 Risk Ratio (M-H, Fixed, 95% CI) 0.27 [0.09, 0.87]
5 Frequency of adverse events 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
 
 
Analysis 1.1.   Comparison 1 Ursodeoxycholic acid versus
placebo or no treatment, Outcome 1 Incidence of hepatic VOD.
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Essell 1998 5/35 13/32 24.15% 0.35[0.14,0.88]
Ohashi 2000 2/71 12/65 22.28% 0.15[0.04,0.66]
Park 2002 13/82 16/83 28.28% 0.82[0.42,1.6]
Ruutu 2002 14/124 14/120 25.3% 0.97[0.48,1.94]
   
Total (95% CI) 312 300 100% 0.6[0.4,0.88]
Total events: 34 (Experimental), 55 (Control)  
Heterogeneity: Tau2=0; Chi2=7.39, df=3(P=0.06); I2=59.41%  
Test for overall effect: Z=2.57(P=0.01)  
Favours ursodeoxycholic 200.05 50.2 1 Favours placebo or none
 
 
Analysis 1.2.   Comparison 1 Ursodeoxycholic acid versus placebo or no treatment, Outcome 2 Overall survival.
Study or subgroup Experimental Control Hazard Ratio Weight Hazard Ratio
  n/N n/N 95% CI   95% CI
Essell 1998 8/35 13/32 16.38% 0.53[0.23,1.26]
Park 2002 9/82 9/83 14.07% 1.6[0.64,4.04]
Ruutu 2002 36/123 53/119 69.55% 0.81[0.53,1.23]
   
Total (95% CI) 240 234 100% 0.83[0.59,1.18]
Total events: 53 (Experimental), 75 (Control)  
Heterogeneity: Tau2=0; Chi2=2.99, df=2(P=0.22); I2=33.05%  
Test for overall effect: Z=1.04(P=0.3)  
Favours ursodeoxycholic 50.2 20.5 1 Favours placebo or none
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Analysis 1.3.   Comparison 1 Ursodeoxycholic acid versus placebo or no
treatment, Outcome 3 All-cause mortality at 100 days post-transplant.
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Essell 1998 8/35 13/32 21.35% 0.56[0.27,1.18]
Ohashi 2000 16/71 16/65 26.26% 0.92[0.5,1.68]
Park 2002 9/82 9/83 14.06% 1.01[0.42,2.42]
Ruutu 2002 13/124 24/120 38.34% 0.52[0.28,0.98]
   
Total (95% CI) 312 300 100% 0.7[0.5,0.99]
Total events: 46 (Experimental), 62 (Control)  
Heterogeneity: Tau2=0; Chi2=2.59, df=3(P=0.46); I2=0%  
Test for overall effect: Z=2.01(P=0.04)  
Favours ursodeoxycholic 50.2 20.5 1 Favours placebo or none
 
 
Analysis 1.4.   Comparison 1 Ursodeoxycholic acid versus placebo
or no treatment, Outcome 4 Mortality attributable to hepatic VOD.
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Essell 1998 1/35 5/32 41.02% 0.18[0.02,1.48]
Ohashi 2000 0/71 0/65   Not estimable
Park 2002 2/82 5/83 39.03% 0.4[0.08,2.03]
Ruutu 2002 0/124 2/120 19.95% 0.19[0.01,3.99]
   
Total (95% CI) 312 300 100% 0.27[0.09,0.87]
Total events: 3 (Experimental), 12 (Control)  
Heterogeneity: Tau2=0; Chi2=0.42, df=2(P=0.81); I2=0%  
Test for overall effect: Z=2.2(P=0.03)  
Favours ursodeoxycholic 2000.005 100.1 1 Favours placebo or none
 
 
Analysis 1.5.   Comparison 1 Ursodeoxycholic acid versus placebo
or no treatment, Outcome 5 Frequency of adverse events.
Study or subgroup Experimental Control Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Park 2002 8/82 9/83 0.9[0.37,2.22]
Favours ursodeoxycholic 50.2 20.5 1 Favours placebo or none
 
 
Comparison 2.   Heparin versus no treatment
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Incidence of hepatic VOD 2 259 Risk Ratio (M-H, Fixed, 95% CI) 0.47 [0.18, 1.26]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
2 Overall survival     Other data No numeric data
3 All-cause mortality at 100 days
post-transplant
1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Mortality attributable to hepat-
ic VOD
1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5 Frequency of adverse events 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
 
 
Analysis 2.1.   Comparison 2 Heparin versus no treatment, Outcome 1 Incidence of hepatic VOD.
Study or subgroup Favours ex-
perimental
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Attal 1992 2/81 11/80 91.25% 0.18[0.04,0.78]
Marsa-Vila 1991 4/52 1/46 8.75% 3.54[0.41,30.53]
   
Total (95% CI) 133 126 100% 0.47[0.18,1.26]
Total events: 6 (Favours experimental), 12 (Control)  
Heterogeneity: Tau2=0; Chi2=5.01, df=1(P=0.03); I2=80.03%  
Test for overall effect: Z=1.5(P=0.13)  
Favours heparin 1000.01 100.1 1 Favours no treatment
 
 
Analysis 2.2.   Comparison 2 Heparin versus no treatment, Outcome 2 Overall survival.
Overall survival
Study Heparin group No treatment group
Attal 1992 92.6% 88.7%
 
 
Analysis 2.3.   Comparison 2 Heparin versus no treatment,
Outcome 3 All-cause mortality at 100 days post-transplant.
Study or subgroup Experimental Control Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Attal 1992 6/81 9/80 0.66[0.25,1.76]
Favours heparin 50.2 20.5 1 Favours no treatment
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Analysis 2.4.   Comparison 2 Heparin versus no treatment, Outcome 4 Mortality attributable to hepatic VOD.
Study or subgroup Experimental Control Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Attal 1992 2/81 7/80 0.28[0.06,1.32]
Favours heparin 200.05 50.2 1 Favours no treatment
 
 
Analysis 2.5.   Comparison 2 Heparin versus no treatment, Outcome 5 Frequency of adverse events.
Study or subgroup Experimental Control Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Attal 1992 3/81 0/80 6.91[0.36,131.75]
Favours heparin 2000.005 100.1 1 Favours no treatment
 
 
Comparison 3.   Low molecular weight heparin versus placebo or no treatment
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Incidence of hepatic VOD 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Frequency of adverse events 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
 
 
Analysis 3.1.   Comparison 3 Low molecular weight heparin versus
placebo or no treatment, Outcome 1 Incidence of hepatic VOD.
Study or subgroup Experimental Control Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Lee 1996 2/23 7/22 0.27[0.06,1.18]
Favours LMWH 200.05 50.2 1 Favours placebo or none
 
 
Analysis 3.2.   Comparison 3 Low molecular weight heparin versus
placebo or no treatment, Outcome 2 Frequency of adverse events.
Study or subgroup Experimental Control Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Or 1996 5/28 8/33 0.74[0.27,2]
Favours LMWH 50.2 20.5 1 Favours placebo or none
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Comparison 4.   Defibrotide versus no treatment
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Incidence of hepatic VOD 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Subgroup analyses of inci-
dence of hepatic VOD by age
groups
1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Infants and children 1   Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Adolescents 1   Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Subgroup analysis for inci-
dence of hepatic VOD by un-
derlying diseases
1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Osteopetrosis 1   Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Diseases other than os-
teopetrosis
1   Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Subgroup analysis of inci-
dence of hepatic VOD by type
of transplant
1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 Allogeneic 1   Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Autologous 1   Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Overall survival 1   Hazard Ratio (95% CI) Totals not selected
6 All-cause mortality at 100
days post-transplant
1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
7 Mortality attributable to he-
patic VOD
1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
8 Frequency of adverse
events
1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
9 Frequency of severe ad-
verse events
1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
10 Frequency of haemor-
rhage
1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
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Analysis 4.1.   Comparison 4 Defibrotide versus no treatment, Outcome 1 Incidence of hepatic VOD.
Study or subgroup Experimental Control Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Corbacioglu 2012 22/181 35/179 0.62[0.38,1.02]
Favours defibrotide 50.2 20.5 1 Favours no treatment
 
 
Analysis 4.2.   Comparison 4 Defibrotide versus no treatment, Outcome
2 Subgroup analyses of incidence of hepatic VOD by age groups.
Study or subgroup Experimental Control Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
4.2.1 Infants and children  
Corbacioglu 2012 19/137 27/136 0.7[0.41,1.19]
   
4.2.2 Adolescents  
Corbacioglu 2012 3/43 8/40 0.35[0.1,1.22]
Favours defibrotide 100.1 50.2 20.5 1 Favours no treatment
 
 
Analysis 4.3.   Comparison 4 Defibrotide versus no treatment, Outcome 3
Subgroup analysis for incidence of hepatic VOD by underlying diseases.
Study or subgroup Experimental Control Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
4.3.1 Osteopetrosis  
Corbacioglu 2012 1/7 4/6 0.21[0.03,1.43]
   
4.3.2 Diseases other than osteopetrosis  
Corbacioglu 2012 21/173 31/170 0.67[0.4,1.11]
Favours defibrotide 500.02 100.1 1 Favours no treatment
 
 
Analysis 4.4.   Comparison 4 Defibrotide versus no treatment, Outcome
4 Subgroup analysis of incidence of hepatic VOD by type of transplant.
Study or subgroup Experimental Control Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
4.4.1 Allogeneic  
Corbacioglu 2012 15/122 25/117 0.58[0.32,1.04]
   
4.4.2 Autologous  
Corbacioglu 2012 7/53 10/55 0.73[0.3,1.77]
Favours defibrotide 50.2 20.5 1 Favours no treatment
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Analysis 4.5.   Comparison 4 Defibrotide versus no treatment, Outcome 5 Overall survival.
Study or subgroup Experimental Control Hazard Ratio Hazard Ratio
  n/N n/N 95% CI 95% CI
Corbacioglu 2012 18/180 17/176 1.04[0.54,2.02]
Favours defibrotide 50.2 20.5 1 Favours no treatment
 
 
Analysis 4.6.   Comparison 4 Defibrotide versus no treatment,
Outcome 6 All-cause mortality at 100 days post-transplant.
Study or subgroup Experimental Control Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Corbacioglu 2012 18/181 17/179 1.05[0.56,1.97]
Favours defibrotide 20.5 1.50.7 1 Favours no treatment
 
 
Analysis 4.7.   Comparison 4 Defibrotide versus no treatment, Outcome 7 Mortality attributable to hepatic VOD.
Study or subgroup Experimental Control Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Corbacioglu 2012 4/181 10/179 0.4[0.13,1.24]
Favours defibrotide 100.1 50.2 20.5 1 Favours no treatment
 
 
Analysis 4.8.   Comparison 4 Defibrotide versus no treatment, Outcome 8 Frequency of adverse events.
Study or subgroup Experimental Control Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Corbacioglu 2012 9/181 0/179 18.79[1.1,320.45]
Favours defibrotide 5000.002 100.1 1 Favours no treatment
 
 
Analysis 4.9.   Comparison 4 Defibrotide versus no treatment, Outcome 9 Frequency of severe adverse events.
Study or subgroup Experimental Control Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Corbacioglu 2012 3/181 0/179 6.92[0.36,133.07]
Favours defibrotide 2000.005 100.1 1 Favours no treatment
 
 
Analysis 4.10.   Comparison 4 Defibrotide versus no treatment, Outcome 10 Frequency of haemorrhage.
Study or subgroup Experimental Control Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Corbacioglu 2012 39/181 37/179 1.04[0.7,1.55]
Favours defibrotide 20.5 1.50.7 1 Favours no treatment
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Comparison 5.   Glutamine versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 All-cause mortality at 100 days post-
transplant
1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Frequency of adverse events 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
 
 
Analysis 5.1.   Comparison 5 Glutamine versus placebo, Outcome 1 All-cause mortality at 100 days post-transplant.
Study or subgroup Experimental Control Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Brown 1998 0/18 1/16 0.3[0.01,6.84]
Favours glutamine 1000.01 100.1 1 Favours placebo
 
 
Analysis 5.2.   Comparison 5 Glutamine versus placebo, Outcome 2 Frequency of adverse events.
Study or subgroup Experimental Control Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Brown 1998 1/18 0/16 2.68[0.12,61.58]
Favours glutamine 1000.01 100.1 1 Favours placebo
 
 
Comparison 6.   Fresh frozen plasma versus no treatment
Outcome or subgroup title No. of
studies
No. of partici-
pants
Statistical method Effect size
1 Incidence of hepatic VOD 2 383 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.20, 2.17]
 
 
Analysis 6.1.   Comparison 6 Fresh frozen plasma versus no treatment, Outcome 1 Incidence of hepatic VOD.
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Matsumoto 2007 0/24 3/23 53.76% 0.14[0.01,2.52]
Yannaki 2012 4/172 3/164 46.24% 1.27[0.29,5.59]
   
Total (95% CI) 196 187 100% 0.66[0.2,2.17]
Total events: 4 (Experimental), 6 (Control)  
Heterogeneity: Tau2=0; Chi2=1.87, df=1(P=0.17); I2=46.53%  
Test for overall effect: Z=0.68(P=0.5)  
Favours FFP 5000.002 100.1 1 Favours no treatment
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Comparison 7.   Antithrombin III plus heparin versus heparin alone
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Incidence of hepatic VOD 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Frequency of adverse events 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
 
 
Analysis 7.1.   Comparison 7 Antithrombin III plus heparin
versus heparin alone, Outcome 1 Incidence of hepatic VOD.
Study or subgroup Experimental Control Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Jung 2005 0/14 4/16 0.13[0.01,2.15]
Favours ATIII + heparin 2000.005 100.1 1 Favours heparin alone
 
 
Analysis 7.2.   Comparison 7 Antithrombin III plus heparin
versus heparin alone, Outcome 2 Frequency of adverse events.
Study or subgroup Experimental Control Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Jung 2005 1/14 4/16 0.29[0.04,2.27]
Favours ATIII + heparin 500.02 100.1 1 Favours heparin alone
 
 
Comparison 8.   Heparin versus low molecular weight heparin
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Incidence of hepatic VOD 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Mortality attributable to hepat-
ic VOD
1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Frequency of adverse events 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
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Analysis 8.1.   Comparison 8 Heparin versus low molecular weight heparin, Outcome 1 Incidence of hepatic VOD.
Study or subgroup Heparin Enoxaparin Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Demuynck 1995 12/47 6/46 1.96[0.8,4.77]
Favours heparin 50.2 20.5 1 Favours enoxaparin
 
 
Analysis 8.2.   Comparison 8 Heparin versus low molecular weight
heparin, Outcome 2 Mortality attributable to hepatic VOD.
Study or subgroup Heparin Enoxaparin Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Demuynck 1995 1/47 0/46 2.94[0.12,70.3]
Favours heparin 1000.01 100.1 1 Favours enoxaparin
 
 
Analysis 8.3.   Comparison 8 Heparin versus low molecular weight heparin, Outcome 3 Frequency of adverse events.
Study or subgroup Heparin Enoxaparin Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Demuynck 1995 6/47 7/46 0.84[0.3,2.31]
Favours heparin 50.2 20.5 1 Favours enoxaparin
 
 
Comparison 9.   Heparin versus prostaglandin E1
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Incidence of hepatic VOD 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Mortality attributable to hepat-
ic VOD
1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Frequency of adverse events 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
 
 
Analysis 9.1.   Comparison 9 Heparin versus prostaglandin E1, Outcome 1 Incidence of hepatic VOD.
Study or subgroup Heparin Prostaglandin E1 Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Demuynck 1995 12/47 10/47 1.2[0.58,2.5]
Favours heparin 50.2 20.5 1 Favours prostaglandin E1
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Analysis 9.2.   Comparison 9 Heparin versus prostaglandin E1, Outcome 2 Mortality attributable to hepatic VOD.
Study or subgroup Heparin Prostaglandin E1 Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Demuynck 1995 1/47 2/47 0.5[0.05,5.33]
Favours heparin 500.02 100.1 1 Favours prostaglandin E1
 
 
Analysis 9.3.   Comparison 9 Heparin versus prostaglandin E1, Outcome 3 Frequency of adverse events.
Study or subgroup Heparin Prostaglandic E1 Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Demuynck 1995 6/47 14/47 0.43[0.18,1.02]
Favours heparin 100.1 50.2 20.5 1 Favours prostaglandin E1
 
 
Comparison 10.   Low molecular weight heparin versus prostaglandin E1
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Incidence of hepatic VOD 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Mortality attributable to hepat-
ic VOD
1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Frequency of adverse events 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
 
 
Analysis 10.1.   Comparison 10 Low molecular weight heparin
versus prostaglandin E1, Outcome 1 Incidence of hepatic VOD.
Study or subgroup Enoxaparin Prostaglandin E1 Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Demuynck 1995 6/46 10/47 0.61[0.24,1.55]
Favours enoxaparin 100.1 50.2 20.5 1 Favours prostaglandin E1
 
 
Analysis 10.2.   Comparison 10 Low molecular weight heparin versus
prostaglandin E1, Outcome 2 Mortality attributable to hepatic VOD.
Study or subgroup Enoxaparin Prostaglandin E1 Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Demuynck 1995 0/46 2/47 0.2[0.01,4.14]
Favours enoxaparin 2000.005 100.1 1 Favours prostaglandin E1
 
 
Interventions for prophylaxis of hepatic veno-occlusive disease in people undergoing haematopoietic stem cell transplantation (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
73
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Analysis 10.3.   Comparison 10 Low molecular weight heparin
versus prostaglandin E1, Outcome 3 Frequency of adverse events.
Study or subgroup Enoxaparin Prostaglandin E1 Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Demuynck 1995 7/46 14/47 0.51[0.23,1.15]
Favours enoxaparin 50.2 20.5 1 Favours prostaglandin E1
 
 
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
 
#1 Stem Cell Transplantation
#2 MeSH descriptor Hematopoietic Stem Cell Transplantation explode all trees
#3 MeSH descriptor Bone Marrow Transplantation explode all trees
#4 MeSH descriptor Peripheral Blood Stem Cell Transplantation explode all trees
#5 MeSH descriptor Cord Blood Stem Cell Transplantation explode all trees
#6 MeSH descriptor Mesenchymal Stem Cell Transplantation explode all trees
#7 (bone marrow NEAR/2 transplant* ) or (bone marrow NEAR/2 graJ* ) or (bone marrow NEAR/2
trasplant* ) or (bone marrow NEAR/2 rescue*)
#8 (stem cell* or stem-cell*)
#9 "progenitor cell*"
#10 (ASCT or ABMT or PBPC or PBSCT or PSCT or BMT or SCT or HSCT)
#11 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10)
#12 MeSH descriptor Transplantation Conditioning explode all trees
#13 myeloablat*
#14 reduced intens*
#15 (nonmyeloablat* or non-myeloablat*)
#16 (mini-tra*splant* or minitra*splant*)
#17 (#12 OR #13 OR #14 OR #15 OR #16)
#18 MeSH descriptor Transplantation, Homologous explode all trees
#19 (allograft* or allo-graJ*)
#20 (allotransplant* or allo-transplant*)
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#21 (allotrasplant* or allo-trasplant*)
#22 (allogen* or allo-gen*)
#23 (allogen* NEAR/5 transplant* ) or (allogen* NEAR/5 trasplant* ) or (allogen* NEAR/5 graJ* ) or (allo-
gen* NEAR/5 rescue*)
#24 (allo-gen* NEAR/5 transplant* ) or (allo-gen* NEAR/5 trasplant* ) or (allo-gen* NEAR/5 graJ* ) or (al-
lo-gen* NEAR/5 rescue*)
#25 (homograft* or homo-graJ*)
#26 homolog*
#27 (homotransplant* or homo-transplant*)
#28 (homotrasplant* or homo-trasplant*)
#29 (#18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28)
#30 MeSH descriptor Transplantation, Autologous explode all trees
#31 (autograft* or auto-graJ*)
#32 (autotransplant* or auto-transplant*)
#33 (autotra*splant* or auto-tra*splant*)
#34 (autolog* NEAR/5 (transplant* or graJ* or trasplant* or rescue*))
#35 (#30 OR #31 OR #32 OR #33 OR #34)
#36 (#11 OR #17 OR #29 OR #35)
#37 MeSH descriptor Hepatic Veno-Occlusive Disease explode all trees
#38 (veno-occlusiv* or venoocclusiv*)
#39 (veno-oclusiv* or venooclusiv*)
#40 (sinusoidal* adj3 obstruct*)
#41 VOD
#42 (#37 OR #38 OR #39 OR #40 OR #41)
#43 (#36 AND #42)
  (Continued)
 
Appendix 2. MEDLINE (OVID) search strategy
 
1 HEPATIC VENO-OCCLUSIVE DISEASE/
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2 (veno-occlusiv$ or venoocclusiv$).tw.
3 (veno-oclusiv$ or venooclusiv$).tw.
4 (sinusoidal$ adj3 obstruct$).tw.
5 VOD.tw.
6 or/1-5
7 exp STEM CELL TRANSPLANTATION/
8 Exp HEMATOPOIETIC STEM CELL TRAN SPLANTATION/
9 Exp BONE MARROW TRANSPLANTATION/
10 PERIPHERAL BLOOD STEM CELL TRANSPLANTATION/
11 CORD BLOOD STEM CELL TRANSPL ANTATION/
12 MESENCHYMAL STEM CELL TRANSP LANTATION/
13 (bone marrow adj2 (transplant$ or graJ$ or trasplant$ or rescue$)).tw.
14 (stem cell$ or stem-cell$).tw.
15 "progenitor cell$".tw.
16 (ASCT or ABMT or PBPC or PBSCT or PSCT or BMT or SCT or HSCT).tw.
17 or/7-16
18 MYELOABLATIVE CONDITIONING/ or NONMYELOABLATIVE CONDITIONING/ or REDUCED INTENSITY
CONDITIONING/
19 myeloablat$.tw.
20 reduced intens$.tw.
21 (nonmyeloablat$ or non-myeloablat$).tw.
22 (mini-tra?splant$ or minitra?splant$).tw.
23 or/18-22
24 exp ALLOTRANSPLANTATION/
25 (allograft$ or allo-graJ$).tw.
26 (allotransplant$ or allo-transplant$).tw.
27 (allotrasplant$ or allo-trasplant$).tw.
28 (allogen$ or allo-gen$).tw.
29 ((allogen$ or allo-gen$) adj5 (transplant$ or trasplant$ or graJ$ or rescue$)).tw.
  (Continued)
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30 (homograft$ or homo-graJ$).tw.
31 homolog*.tw.
32 (homotransplant$ or homo-transplant$).tw.
33 (homotrasplant$ or homo-trasplant$).tw.
34 or/24-33
35 AUTOTRANSPLANTATION/
36 (autograft$ or auto-graJ$).tw.
37 (autotransplant$ or auto-transplant$).tw.
38 (autotra?splant$ or auto-tra?splant$).tw.
39 (autolog$ adj5 (transplant$ or graJ$ or trasplant$ or rescue$)).tw.
40 or/35-39
41 17 or 23 or 34 or 40
42 6 and 41
43 randomised controlled trial.pt.
44 controlled clinical trial.pt.
45 randomized.ab.
46 placebo.ab.
47 drug therapy.fs.
48 randomly.ab.
49 trial.ab.
50 groups.ab.
51 or/43-50
52 humans.sh.
53 51 and 52
54 42 and 53
  (Continued)
 
Appendix 3. EMBASE (OVID) search strategy
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1 LIVER VENOOCCLUSIVE DISEASE/
2 (veno-occlusiv$ or venoocclusiv$).tw.
3 (veno-oclusiv$ or venooclusiv$).tw.
4 (sinusoidal$ adj3 obstruct$).tw.
5 VOD.tw.
6 or/1-5
7 exp STEM CELL TRANSPLANTATION/
8 Exp HEMATOPOIETIC STEM CELL TRAN SPLANTATION/
9 Exp BONE MARROW TRANSPLANTATION/
10 PERIPHERAL BLOOD STEM CELL TRANSPLANTATION/
11 CORD BLOOD STEM CELL TRANSPL ANTATION/
12 MESENCHYMAL STEM CELL TRANSP LANTATION/
13 (bone marrow adj2 (transplant$ or graJ$ or trasplant$ or rescue$)).tw.
14 (stem cell$ or stem-cell$).tw.
15 "progenitor cell$".tw.
16 (ASCT or ABMT or PBPC or PBSCT or PSCT or BMT or SCT or HSCT).tw.
17 or/7-16
18 (MYELOABLATIVE CONDITIONING or NONMYELOABLATIVE CONDITIONING or REDUCED INTENSITY
CONDITIONING).sh,hw.
19 myeloablat$.tw.
20 reduced intens$.tw.
21 (nonmyeloablat$ or non-myeloablat$).tw.
22 (mini-tra?splant$ or minitra?splant$).tw.
23 or/18-22
24 exp ALLOTRANSPLANTATION/
25 (allograft$ or allo-graJ$).tw.
26 (allotransplant$ or allo-transplant$).tw.
27 (allotrasplant$ or allo-trasplant$).tw.
28 (allogen$ or allo-gen$).tw.
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29 ((allogen$ or allo-gen$) adj5 (transplant$ or trasplant$ or graJ$ or rescue$)).tw.
30 (homograft$ or homo-graJ$).tw.
31 homolog*.tw.
32 (homotransplant$ or homo-transplant$).tw.
33 (homotrasplant$ or homo-trasplant$).tw.
34 or/24-33
35 AUTOTRANSPLANTATION/
36 (autograft$ or auto-graJ$).tw.
37 (autotransplant$ or auto-transplant$).tw.
38 (autotra?splant$ or auto-tra?splant$).tw.
39 (autolog$ adj5 (transplant$ or graJ$ or trasplant$ or rescue$)).tw.
40 or/35-39
41 17 or 23 or 34 or 40
42 6 and 41
43 (random$ or placebo$ or single blind$ or double blind$ or triple blind$).ti,ab.
44 RETRACTED ARTICLE/
45 or/43-44
46 (animal$ not human$).sh,hw.
47 (book or conference paper or editorial or letter or review).pt. not exp randomised controlled trial/
48 (random sampl$ or random digit$ or random effect$ or random survey or random regression).ti,ab.
not exp randomised controlled trial/
49 45 not (46 or 47 or 48)
50 42 and 49
  (Continued)
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
We did not produce a funnel plot because of insuKicient number of studies identified. We did not conduct sensitivity analyses because all
studies had high risk of bias. We assessed subgroup diKerences by examining the I2 statistic and performing Chi2 test for heterogeneity
across subgroup results. For outcomes with substantial heterogeneity, we performed random-eKects meta-analyses as a sensitivity
analysis. We did not impute missing data, except for mortality and incidence of hepatic VOD data, but assumed that participants had not
died or developed VOD if their data were missing.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Antithrombin III  [therapeutic use];  Cause of Death;  Cholagogues and Choleretics  [*therapeutic use];  Glutamine  [therapeutic use]; 
Hematopoietic Stem Cell Transplantation  [*adverse eKects];  Heparin, Low-Molecular-Weight  [therapeutic use];  Hepatic Veno-Occlusive
Disease  [mortality]  [*prevention & control];  Plasma;  Polydeoxyribonucleotides  [therapeutic use];  Randomized Controlled Trials as
Topic;  Ursodeoxycholic Acid  [*therapeutic use]
MeSH check words
Female; Humans; Male
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